(trifluoromethyl)benzene - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	(trifluoromethyl)benzene	go back to main search page
Accession:	CHEBI:36810	browse the term
Definition:	A fluorohydrocarbon that is fluoroform in which the hydrogen is substituted by a phenyl group.
Synonyms:	related_synonym:	C6H5CF3; CF3Ph; Formula=C7H5F3; InChI=1S/C7H5F3/c8-7(9,10)6-4-2-1-3-5-6/h1-5H; InChIKey=GETTZEONDQJALK-UHFFFAOYSA-N; PhCF3; SMILES=FC(F)(F)c1ccccc1; alpha,alpha,alpha-trifluorotoluene; benzotrifluoride; omega-trifluorotoluene; phenylfluoroform; trifluoromethylbenzene
	xref:	CAS:98-08-8; Gmelin:3670; PMID:11671431; PMID:20958547; PMID:24267073; PMID:24669762; Reaxys:1906908

show annotations for term's descendants Sort by:
Rat (440) Mouse (441) Human (442) Chinchilla (0) Bonobo (0) Dog (1) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (440)

flufenamic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ADAM metallopeptidase domain 17

increases response to substance

ADAM17 results in increased susceptibility to Flufenamic Acid

NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639

G

aldo-keto reductase family 1, member C1

decreases activity
multiple interactions

Flufenamic Acid results in decreased activity of AKR1C1 protein
Flufenamic Acid inhibits the reaction [AKR1C1 protein affects the susceptibility to Oxaliplatin]; Flufenamic Acid inhibits the reaction [AKR1C1 protein results in increased metabolism of Dihydrotestosterone]

PMID:8573067 PMID:12604236 PMID:14672942 PMID:23933386

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

aldo-keto reductase family 1, member C2

multiple interactions
decreases activity

Flufenamic Acid inhibits the reaction [AKR1C2 protein results in increased metabolism of Dihydrotestosterone]
Flufenamic Acid results in decreased activity of AKR1C2 protein

PMID:8573067 PMID:12604236 PMID:14672942

NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764

G

aldo-keto reductase family 1, member C3

affects binding
multiple interactions
decreases activity

Flufenamic Acid binds to AKR1C3 protein
Flufenamic Acid inhibits the reaction [AKR1C3 protein affects the susceptibility to oxaliplatin]; Flufenamic Acid inhibits the reaction [AKR1C3 protein results in increased metabolism of Dihydrotestosterone]
Flufenamic Acid results in decreased activity of AKR1C3 protein

PMID:12604236 PMID:14672942 PMID:14996743 PMID:23933386

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

androgen receptor

multiple interactions
decreases expression

Flufenamic Acid analog binds to and results in decreased activity of AR protein; Flufenamic Acid binds to and results in decreased activity of AR protein
Flufenamic Acid results in decreased expression of AR mRNA; Flufenamic Acid results in decreased expression of AR protein

PMID:10537180 PMID:19645433

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

acid sensing ion channel subunit family member 5

multiple interactions

Flufenamic Acid binds to and results in increased activity of ASIC5 protein

NCBI chr 2:167,307,984...167,336,812
Ensembl chr 2:167,307,984...167,336,812

G

BCL2-associated agonist of cell death

multiple interactions

Flufenamic Acid inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAD protein]

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2-antagonist/killer 1

multiple interactions

Flufenamic Acid inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAK1 protein]

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

bestrophin 1

decreases activity

Flufenamic Acid results in decreased activity of BEST1 protein

NCBI chr 1:206,629,340...206,646,085
Ensembl chr 1:206,629,500...206,646,063

G

BH3 interacting domain death agonist

multiple interactions

Flufenamic Acid inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BID protein]

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

caspase 3

multiple interactions

Flufenamic Acid inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 protein modified form]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

calcium-sensing receptor

multiple interactions

Flufenamic Acid promotes the reaction [CASR protein results in increased uptake of Calcium]

NCBI chr11:64,235,251...64,304,811
Ensembl chr11:64,235,251...64,304,811

G

CF transmembrane conductance regulator

decreases activity

Flufenamic Acid results in decreased activity of CFTR protein

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

glycoprotein hormones, alpha polypeptide

multiple interactions

[Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of CGA mRNA

NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191

G

cholinergic receptor, muscarinic 1

multiple interactions

Flufenamic Acid inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]

NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356

G

dehydrogenase/reductase 11

decreases activity

Flufenamic Acid results in decreased activity of DHRS11 protein

NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295

G

follicle stimulating hormone subunit beta

multiple interactions

[Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of FSHB mRNA

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

glutamate metabotropic receptor 1

multiple interactions

Flufenamic Acid inhibits the reaction [3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein]; Flufenamic Acid inhibits the reaction [[3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein] which results in increased abundance of Calcium]

NCBI chr 1:5,058,285...5,453,170
Ensembl chr 1:5,058,292...5,453,170

G

glutathione S-transferase pi 1

multiple interactions

Flufenamic Acid inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

interleukin 1 alpha

multiple interactions

Flufenamic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein]

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 6

increases expression
multiple interactions

Flufenamic Acid results in increased expression of IL6 mRNA
Flufenamic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]

PMID:15135310 PMID:24849676

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

potassium voltage-gated channel subfamily H member 2

multiple interactions

E 4031 inhibits the reaction [Flufenamic Acid promotes the reaction [KCNH2 protein results in increased transport of Potassium]]; Flufenamic Acid promotes the reaction [KCNH2 protein results in increased transport of Potassium]

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

potassium two pore domain channel subfamily K member 10

multiple interactions

Flufenamic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]

NCBI chr 6:117,690,052...117,826,120
Ensembl chr 6:117,694,222...117,825,695

G

potassium two pore domain channel subfamily K member 2

multiple interactions

Flufenamic Acid promotes the reaction [KCNK2 protein results in increased transport of Potassium]

NCBI chr13:100,766,101...100,963,435
Ensembl chr13:100,766,113...100,963,435

G

potassium two pore domain channel subfamily K member 4

multiple interactions

Flufenamic Acid promotes the reaction [KCNK4 protein results in increased transport of Potassium]

NCBI chr 1:204,117,941...204,129,494
Ensembl chr 1:204,114,572...204,125,925

G

KiSS-1 metastasis-suppressor

multiple interactions

Flufenamic Acid inhibits the reaction [[KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium]

NCBI chr13:44,775,106...44,780,707
Ensembl chr13:44,774,823...44,780,612

G

KISS1 receptor

multiple interactions

Flufenamic Acid inhibits the reaction [[KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium]

NCBI chr 7:9,785,135...9,790,283
Ensembl chr 7:9,785,135...9,788,793

G

low density lipoprotein receptor

multiple interactions
increases expression

Flufenamic Acid inhibits the reaction [Cyclosporine inhibits the reaction [[Cholesterol, LDL binds to LDLR protein] which results in increased degradation of Cholesterol, LDL]]; Flufenamic Acid promotes the reaction [[Cholesterol, LDL binds to LDLR protein] which results in increased degradation of Cholesterol, LDL]; Flufenamic Acid promotes the reaction [Cholesterol, LDL binds to LDLR protein]
Flufenamic Acid results in increased expression of LDLR mRNA; Flufenamic Acid results in increased expression of LDLR protein

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

leptin

multiple interactions

Flufenamic Acid inhibits the reaction [LEP protein results in increased transport of Calcium]

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

luteinizing hormone subunit beta

multiple interactions

[Flufenamic Acid results in decreased abundance of Cyclic AMP] which results in decreased expression of LHB mRNA

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

NK3 homeobox 1

multiple interactions

Flufenamic Acid inhibits the reaction [mibolerone results in increased expression of NKX3-1 mRNA]

NCBI chr15:44,473,851...44,476,443
Ensembl chr15:44,473,851...44,476,441

G

nitric oxide synthase 2

multiple interactions
increases expression

Flufenamic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
Flufenamic Acid results in increased expression of NOS2 mRNA

PMID:10866999 PMID:15135310

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

Pannexin 1

decreases activity

Flufenamic Acid results in decreased activity of PANX1 protein

NCBI chr 8:11,851,176...11,889,774
Ensembl chr 8:11,850,730...11,889,774

G

peroxisome proliferator activated receptor alpha

multiple interactions

Flufenamic Acid binds to and results in increased activity of PPARA protein

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

multiple interactions
increases activity

[Flufenamic Acid results in increased activity of PPARG protein] which results in increased expression of PTGS2 protein; Flufenamic Acid binds to and results in increased activity of PPARG protein

PMID:9013583 PMID:10866999

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

[Flufenamic Acid results in increased activity of PPARG protein] which results in increased expression of PTGS2 protein; Flufenamic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Flufenamic Acid inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]
Flufenamic Acid results in increased expression of PTGS2 mRNA; Flufenamic Acid results in increased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

selectin L

decreases expression

Flufenamic Acid results in decreased expression of SELL protein

NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456

G

solute carrier family 6 member 11

multiple interactions

Flufenamic Acid inhibits the reaction [SLC6A11 protein results in increased uptake of gamma-Aminobutyric Acid]

NCBI chr 4:147,297,972...147,413,319
Ensembl chr 4:147,297,969...147,413,443

G

tumor necrosis factor

multiple interactions
increases expression

Flufenamic Acid inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]
Flufenamic Acid results in increased expression of TNF mRNA

PMID:10866999 PMID:15135310

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

transient receptor potential cation channel, subfamily C, member 6

multiple interactions
increases activity

[Flufenamic Acid results in increased activity of TRPC6 protein] which results in increased uptake of Calcium
Flufenamic Acid inhibits the reaction [1-oleoyl-2-acetoyl-sn-glycerol promotes the reaction [TRPC6 protein results in increased uptake of Calcium]]; Flufenamic Acid inhibits the reaction [1-oleoyl-2-acetoyl-sn-glycerol promotes the reaction [TRPC6 protein results in increased uptake of Manganese]]

PMID:11535132 PMID:14551041 PMID:21562303

NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092

G

transient receptor potential cation channel, subfamily M, member 2

multiple interactions

Flufenamic Acid inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]]

NCBI chr20:10,703,568...10,753,189
Ensembl chr20:10,707,014...10,753,181

G

transient receptor potential cation channel, subfamily M, member 4

decreases activity

Flufenamic Acid results in decreased activity of TRPM4 protein

PMID:16966582 PMID:17188667

NCBI chr 1:95,781,805...95,812,095
Ensembl chr 1:95,782,000...95,812,532

fluoxetine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AP2 associated kinase 1

decreases expression

Fluoxetine results in decreased expression of AAK1 mRNA

NCBI chr 4:119,300,128...119,451,834
Ensembl chr 4:119,295,257...119,450,969

G

aralkylamine N-acetyltransferase

increases expression

Fluoxetine results in increased expression of AANAT mRNA

PMID:9951564 PMID:22291481

NCBI chr10:101,827,072...101,831,805
Ensembl chr10:101,827,301...101,831,801

G

ATP binding cassette subfamily A member 1

decreases expression

Fluoxetine results in decreased expression of ABCA1 mRNA

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 1A

multiple interactions

[[ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] affects the susceptibility to Fluoxetine] which affects the abundance of Olanzapine; [[ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] affects the susceptibility to Fluoxetine] which results in increased uptake of Olanzapine; [ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] affects the susceptibility to Fluoxetine

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

multiple interactions

[[ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] affects the susceptibility to Fluoxetine] which affects the abundance of Olanzapine; [[ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] affects the susceptibility to Fluoxetine] which results in increased uptake of Olanzapine; [ABCB1A gene mutant form co-treated with ABCB1B gene mutant form] affects the susceptibility to Fluoxetine

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily C member 2

increases expression

Fluoxetine results in increased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

acetyl-CoA carboxylase alpha

increases expression

Fluoxetine results in increased expression of ACACA mRNA

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acid phosphatase 5, tartrate resistant

multiple interactions

Fluoxetine inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]

NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929

G

acyl-CoA synthetase long-chain family member 3

increases expression

Fluoxetine results in increased expression of ACSL3 mRNA

NCBI chr 9:80,115,164...80,164,636
Ensembl chr 9:80,115,112...80,164,627

G

acyl-CoA synthetase long-chain family member 4

increases expression

Fluoxetine results in increased expression of ACSL4 mRNA

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

acyl-CoA synthetase short-chain family member 2

increases expression

Fluoxetine results in increased expression of ACSS2 mRNA

NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675

G

ADAM metallopeptidase domain 10

increases expression

Fluoxetine results in increased expression of ADAM10 mRNA

NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889

G

adenosine deaminase, RNA-specific, B1

multiple interactions
increases expression

ADARB1 protein inhibits the reaction [Fluoxetine inhibits the reaction [Excitatory Amino Acid Agents results in increased phosphorylation of MAPK1 protein]]; ADARB1 protein inhibits the reaction [Fluoxetine inhibits the reaction [Excitatory Amino Acid Agents results in increased phosphorylation of MAPK3 protein]]; ADARB1 protein promotes the reaction [Fluoxetine results in increased expression of GRIK2 mRNA]; ADARB1 protein promotes the reaction [Fluoxetine results in increased expression of GRIK2 protein]; HTR2B protein promotes the reaction [Fluoxetine results in increased expression of ADARB1 mRNA]; HTR2B protein promotes the reaction [Fluoxetine results in increased expression of ADARB1 protein]
Fluoxetine results in increased expression of ADARB1 mRNA; Fluoxetine results in increased expression of ADARB1 protein

NCBI chr20:11,222,569...11,350,854
Ensembl chr20:11,222,583...11,350,852

G

adenylate cyclase 8

decreases expression

Fluoxetine results in decreased expression of ADCY8 mRNA

NCBI chr 7:96,417,310...96,665,911
Ensembl chr 7:96,417,324...96,665,911

G

adenosine A1 receptor

multiple interactions

[Fluoxetine co-treated with Caffeine deficiency] results in increased expression of ADORA1 mRNA

NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801

G

aldolase, fructose-bisphosphate C

increases expression

Fluoxetine results in increased expression of ALDOC mRNA

NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066

G

amelogenin, X-linked

decreases expression

Fluoxetine results in decreased expression of AMELX mRNA

NCBI chr X:25,076,362...25,087,660
Ensembl chr X:25,076,362...25,087,660

G

adenosine monophosphate deaminase 2

increases expression

Fluoxetine results in increased expression of AMPD2 mRNA

NCBI chr 2:195,707,609...195,720,454
Ensembl chr 2:195,707,610...195,720,271

G

anoctamin 3

decreases expression

Fluoxetine results in decreased expression of ANO3 mRNA

NCBI chr 3:97,235,671...97,550,090
Ensembl chr 3:97,238,354...97,550,154

G

acidic nuclear phosphoprotein 32 family member A

decreases expression

Fluoxetine results in decreased expression of ANP32A mRNA

NCBI chr 8:62,829,099...62,865,443
Ensembl chr 8:62,827,456...62,865,443

G

annexin A1

decreases expression

Fluoxetine results in decreased expression of ANXA1 mRNA

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

annexin A5

multiple interactions
affects expression

Fluoxetine promotes the reaction [Phosphatidylserines binds to ANXA5 protein]
Fluoxetine affects the expression of ANXA5 mRNA

PMID:16076491 PMID:21852994

NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369

G

adaptor related protein complex 1 subunit sigma 1

decreases expression

Fluoxetine results in decreased expression of AP1S1 mRNA

NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713

G

adaptor related protein complex 2 subunit alpha 2

multiple interactions

Fluoxetine inhibits the reaction [NTRK2 protein binds to AP2A2 protein]

NCBI chr 1:196,652,315...196,725,609
Ensembl chr 1:196,652,337...196,725,603

G

adaptor related protein complex 2 subunit beta 1

multiple interactions

Fluoxetine inhibits the reaction [NTRK2 protein binds to AP2B1 protein]

NCBI chr10:68,099,397...68,205,023
Ensembl chr10:68,099,547...68,205,013

G

adaptor related protein complex 2 subunit mu 1

multiple interactions

Fluoxetine inhibits the reaction [NTRK2 protein binds to AP2M1 protein]

NCBI chr11:80,355,307...80,364,218
Ensembl chr11:80,328,041...80,364,140

G

aquaporin 3 (Gill blood group)

multiple interactions

Fluoxetine inhibits the reaction [Serotonin results in increased expression of AQP3 mRNA]
Fluoxetine inhibits the reaction [Serotonin results in increased expression of AQP3 protein]

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

activity-regulated cytoskeleton-associated protein

decreases expression
increases expression

Fluoxetine results in decreased expression of ARC mRNA
Fluoxetine results in increased expression of ARC mRNA

PMID:15381288 PMID:17033635 PMID:18301726

NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378

G

ARF like GTPase 4D

increases expression

Fluoxetine results in increased expression of ARL4D mRNA

NCBI chr10:86,592,054...86,602,843
Ensembl chr10:86,595,661...86,602,836

G

arrestin, beta 1

multiple interactions

Fluoxetine inhibits the reaction [Corticosterone results in decreased expression of ARRB1 mRNA]

NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061

G

arrestin, beta 2

multiple interactions
increases response to substance

ARRB2 protein promotes the reaction [Fluoxetine results in increased expression of CREB1 protein]; ARRB2 protein promotes the reaction [Fluoxetine results in increased expression of MAPK3 protein]; Fluoxetine inhibits the reaction [Corticosterone results in decreased expression of ARRB2 mRNA]
ARRB2 protein results in increased susceptibility to Fluoxetine

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

N-acylsphingosine amidohydrolase 1

increases expression

Fluoxetine results in increased expression of ASAH1 mRNA

PMID:15342952 PMID:17567588

NCBI chr16:50,966,404...50,997,827
Ensembl chr16:50,966,229...51,008,233

G

asparagine synthetase (glutamine-hydrolyzing)

increases expression

Fluoxetine results in increased expression of ASNS mRNA

PMID:15342952 PMID:17175557 PMID:17567588

NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

increases expression

Fluoxetine results in increased expression of ATP2A2 mRNA

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

arginine vasopressin

decreases expression

Fluoxetine results in decreased expression of AVP mRNA

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

BCL2-associated agonist of cell death

increases expression

Fluoxetine results in increased expression of BAD mRNA

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BAR/IMD domain containing adaptor protein 2

decreases expression

Fluoxetine results in decreased expression of BAIAP2 mRNA

NCBI chr10:105,223,065...105,290,130
Ensembl chr10:105,223,090...105,290,134

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

Fluoxetine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]
vinpocetine inhibits the reaction [Fluoxetine results in increased expression of BAX mRNA]

PMID:34669537 PMID:36169195

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL11 transcription factor B

decreases expression

Fluoxetine results in decreased expression of BCL11B mRNA

NCBI chr 6:126,834,531...126,927,720
Ensembl chr 6:126,834,531...126,928,224

G

BCL2, apoptosis regulator

decreases response to substance
multiple interactions
decreases expression

BCL2 protein results in decreased susceptibility to Fluoxetine
vinpocetine inhibits the reaction [Fluoxetine results in decreased expression of BCL2 mRNA]
Fluoxetine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]
Fluoxetine results in decreased expression of BCL2 mRNA; Fluoxetine results in decreased expression of BCL2 protein

PMID:16076491 PMID:19298536 PMID:21497159 PMID:34669537 PMID:36169195

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

increases expression
decreases expression
affects expression

Fluoxetine results in increased expression of BCL2L1 mRNA; Fluoxetine results in increased expression of BCL2L1 protein
Fluoxetine results in decreased expression of BCL2L1 protein
Fluoxetine affects the expression of BCL2L1 mRNA

PMID:19298536 PMID:21740920 PMID:21852994

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

brain-derived neurotrophic factor

decreases response to substance
increases expression
multiple interactions
decreases expression
affects expression
affects response to substance
increases response to substance

BDNF protein mutant form results in decreased susceptibility to Fluoxetine
Fluoxetine results in increased expression of BDNF mRNA; Fluoxetine results in increased expression of BDNF protein
Fluoxetine affects the reaction [sodium arsenate affects the expression of BDNF protein]
Fluoxetine results in decreased expression of BDNF mRNA
Fluoxetine affects the expression of BDNF mRNA
Fluoxetine results in increased expression of BDNF mRNA; Fluoxetine results in increased expression of BDNF mRNA alternative form; Fluoxetine results in increased expression of BDNF protein
BDNF gene polymorphism affects the susceptibility to Fluoxetine
BDNF protein results in increased susceptibility to Fluoxetine
[Fluoxetine co-treated with Amantadine] results in increased expression of BDNF mRNA; [Fluoxetine co-treated with Ketanserin] results in increased expression of BDNF mRNA; Fluoxetine inhibits the reaction [Reserpine results in decreased expression of BDNF protein]

PMID:8601816 PMID:12504921 PMID:15381288 PMID:15456934 PMID:15555640 More...

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

beclin 1

increases expression

Fluoxetine results in increased expression of BECN1 protein

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

Bet1 golgi vesicular membrane trafficking protein-like

increases expression

Fluoxetine results in increased expression of BET1L mRNA

NCBI chr 1:195,931,407...195,935,072
Ensembl chr 1:195,931,411...195,935,040

G

basic helix-loop-helix ARNT like 1

increases expression
increases expression

Fluoxetine results in increased expression of BMAL1 mRNA
fluoxetine increases expression of Bmal1 mRNA in hippocampal formation

CTD
RGD

PMID:15994025 PMID:15994025

NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231

G

bone morphogenetic protein receptor type 2

multiple interactions

Fluoxetine inhibits the reaction [Monocrotaline results in decreased expression of BMPR2 mRNA]

NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809

G

brain protein I3

increases expression

Fluoxetine results in increased expression of BRI3 mRNA

NCBI chr12:10,341,007...10,364,655
Ensembl chr12:10,341,011...10,364,735

G

bombesin receptor subtype 3

decreases expression

Fluoxetine results in decreased expression of BRS3 mRNA

NCBI chr X:134,906,817...134,932,321
Ensembl chr X:134,906,784...134,930,983

G

complement C1q like 3

decreases expression

Fluoxetine results in decreased expression of C1QL3 mRNA

NCBI chr17:76,119,344...76,129,170
Ensembl chr17:76,119,447...76,128,530

G

calcium voltage-gated channel subunit alpha1 G

affects expression

Fluoxetine affects the expression of CACNA1G mRNA

NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752

G

calcium voltage-gated channel subunit alpha1 H

decreases expression

Fluoxetine results in decreased expression of CACNA1H mRNA

NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376

G

calcium/calmodulin-dependent protein kinase IV

decreases expression
multiple interactions

Fluoxetine results in decreased expression of CAMK4 mRNA
Fluoxetine results in increased phosphorylation of and results in increased activity of CAMK4 protein

PMID:15138445 PMID:17033635

NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487

G

CART prepropeptide

decreases expression

Fluoxetine results in decreased expression of CARTPT protein

NCBI chr 2:31,255,098...31,257,452
Ensembl chr 2:31,255,098...31,290,713

G

caspase 1

increases expression

Fluoxetine results in increased expression of CASP1 mRNA

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

multiple interactions
increases activity
increases cleavage

Fluoxetine inhibits the reaction [Monocrotaline results in decreased expression of CASP3 protein]; Fluoxetine promotes the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein]; vinpocetine inhibits the reaction [Fluoxetine results in increased activity of CASP3 protein]
Palmitic Acid promotes the reaction [Fluoxetine results in increased activity of CASP3 protein]
Fluoxetine results in increased cleavage of CASP3 protein

PMID:18371935 PMID:19135049 PMID:19298536 PMID:21619414 PMID:22700542 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

increases activity
multiple interactions

Fluoxetine results in increased activity of CASP7 protein
Palmitic Acid promotes the reaction [Fluoxetine results in increased activity of CASP7 protein]

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

caspase 8

increases activity

Fluoxetine results in increased activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases activity

Fluoxetine results in increased activity of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

decreases activity
multiple interactions

Fluoxetine results in decreased activity of CAT protein
Resveratrol inhibits the reaction [Fluoxetine results in decreased activity of CAT protein]; vinpocetine inhibits the reaction [Fluoxetine results in decreased activity of CAT protein]

PMID:26348076 PMID:34669537

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cholecystokinin

decreases expression

Fluoxetine results in decreased expression of CCK mRNA

PMID:17033635 PMID:17105902

NCBI chr 8:121,153,499...121,160,194
Ensembl chr 8:121,153,500...121,160,084

G

C-C motif chemokine ligand 2

decreases secretion

Fluoxetine results in decreased secretion of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

multiple interactions

Fluoxetine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cellular communication network factor 3

decreases expression

Fluoxetine results in decreased expression of CCN3 mRNA

NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:86,094,000...86,101,019

G

cyclin A2

decreases expression

Fluoxetine results in decreased expression of CCNA2 mRNA; Fluoxetine results in decreased expression of CCNA2 protein

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

decreases expression

Fluoxetine results in decreased expression of CCNB1 mRNA

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

decreases expression
multiple interactions
increases expression

Fluoxetine results in decreased expression of CCND1 mRNA
N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide inhibits the reaction [Fluoxetine results in increased expression of CCND1 mRNA]; N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide inhibits the reaction [Fluoxetine results in increased expression of CCND1 protein]
Fluoxetine results in increased expression of CCND1 mRNA; Fluoxetine results in increased expression of CCND1 protein

PMID:18573488 PMID:18836303

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D3

decreases expression

Fluoxetine results in decreased expression of CCND3 mRNA

NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371

G

cyclin E1

decreases expression
affects expression
multiple interactions

Fluoxetine results in decreased expression of CCNE1 mRNA
Fluoxetine affects the expression of CCNE1 mRNA
[Fluoxetine results in decreased activity of CKS1B protein] which results in decreased degradation of CCNE1 protein

PMID:18371935 PMID:21497159

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cyclin G2

increases expression

Fluoxetine results in increased expression of CCNG2 mRNA

NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830

G

CD36 molecule

increases expression
multiple interactions

Fluoxetine results in increased expression of CD36 mRNA
SC 560 inhibits the reaction [Fluoxetine results in increased expression of CD36 mRNA]

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

CD8 subunit alpha

increases expression

Fluoxetine results in increased expression of CD8A protein

NCBI chr 4:103,365,804...103,370,041
Ensembl chr 4:103,365,804...103,370,040

G

cyclin-dependent kinase 5

decreases expression

Fluoxetine results in decreased expression of CDK5 mRNA

NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression
affects expression

[Fluoxetine results in decreased activity of CKS1B protein] which results in decreased degradation of CDKN1A protein
Fluoxetine results in increased expression of CDKN1A mRNA
Fluoxetine affects the expression of CDKN1A mRNA

PMID:18371935 PMID:18836303

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

increases expression
affects expression
multiple interactions

Fluoxetine results in increased expression of CDKN1B mRNA
Fluoxetine affects the expression of CDKN1B mRNA
[Fluoxetine results in decreased activity of CKS1B protein] which results in decreased degradation of CDKN1B protein

PMID:18371935 PMID:21497159

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 2A

increases expression

Fluoxetine results in increased expression of CDKN2A mRNA

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

cyclin-dependent kinase inhibitor 2B

increases expression

Fluoxetine results in increased expression of CDKN2B mRNA

NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050

G

caudal type homeo box 1

affects expression

Fluoxetine affects the expression of CDX1 mRNA

NCBI chr18:54,472,587...54,490,913
Ensembl chr18:54,473,444...54,490,814

G

carboxylesterase 1D

multiple interactions

Fluoxetine inhibits the reaction [CES1 protein results in increased hydrolysis of 4-nitrophenyl acetate]; Fluoxetine inhibits the reaction [CES1 protein results in increased hydrolysis of Methylphenidate]

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

cholinergic receptor nicotinic alpha 5 subunit

decreases expression

Fluoxetine results in decreased expression of CHRNA5 mRNA

NCBI chr 8:55,369,794...55,398,526
Ensembl chr 8:55,369,794...55,398,146

G

cholinergic receptor nicotinic beta 4 subunit

decreases expression

Fluoxetine results in decreased expression of CHRNB4 mRNA

NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027

G

CDC28 protein kinase regulatory subunit 1B

multiple interactions
decreases expression

[Fluoxetine results in decreased activity of CKS1B protein] which results in decreased degradation of CCNE1 protein; [Fluoxetine results in decreased activity of CKS1B protein] which results in decreased degradation of CDKN1A protein; [Fluoxetine results in decreased activity of CKS1B protein] which results in decreased degradation of CDKN1B protein; Fluoxetine binds to and results in decreased activity of CKS1B protein
Fluoxetine results in decreased expression of CKS1B mRNA

NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636

G

clock circadian regulator

increases expression
increases expression

Fluoxetine results in increased expression of CLOCK mRNA
fluoxetine increases expression of Clock mRNA in hippocampal formation

CTD
RGD

PMID:15994025 PMID:15994025

NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400

G

connector enhancer of kinase suppressor of Ras 2

decreases expression

Fluoxetine results in decreased expression of CNKSR2 mRNA

NCBI chr X:36,908,135...37,148,337
Ensembl chr X:36,907,850...37,150,555

G

cannabinoid receptor 1

multiple interactions
decreases expression

[Fluoxetine affects the susceptibility to Ethanol] which affects the expression of CNR1 mRNA; Fluoxetine results in decreased expression of and results in decreased phosphorylation of CNR1 protein
Fluoxetine results in decreased expression of CNR1 mRNA

PMID:15936043 PMID:18722357 PMID:31339221

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

cAMP responsive element binding protein 1

increases expression
decreases expression
increases phosphorylation
multiple interactions

Fluoxetine results in increased expression of CREB1 mRNA
Fluoxetine results in decreased expression of CREB1 mRNA
Fluoxetine results in increased phosphorylation of CREB1 protein
Fluoxetine results in increased expression of CREB1 protein
ARRB2 protein promotes the reaction [Fluoxetine results in increased expression of CREB1 protein]; Fluoxetine affects the reaction [sodium arsenate affects the expression of CREB1 protein]; Fluoxetine results in decreased phosphorylation of and results in decreased activity of CREB1 protein
[Fluoxetine co-treated with Methylphenidate] results in increased expression of CREB1 mRNA; [Fluoxetine co-treated with Methylphenidate] results in increased phosphorylation of CREB1 protein; [Fluoxetine co-treated with Olanzapine] results in decreased phosphorylation of CREB1 protein; Fluoxetine results in increased phosphorylation of and results in increased activity of CREB1 protein; Fluoxetine results in increased phosphorylation of and results in increased localization of CREB1 protein; N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide inhibits the reaction [Fluoxetine results in increased phosphorylation of and results in increased activity of CREB1 protein]; staurosporine aglycone inhibits the reaction [Fluoxetine results in increased phosphorylation of CREB1 protein]

PMID:8601816 PMID:14556240 PMID:15138445 PMID:16887358 PMID:18573488 More...

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

corticotropin releasing hormone

decreases expression
increases expression

Fluoxetine results in decreased expression of CRH mRNA
Fluoxetine results in increased expression of CRH mRNA

PMID:1351783 PMID:9740405 PMID:20374287

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

corticotropin releasing hormone receptor 1

increases expression

Fluoxetine results in increased expression of CRHR1 mRNA

NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481

G

cryptochrome circadian regulator 1

affects expression
increases expression

Fluoxetine affects the expression of CRY1 mRNA
fluoxetine increases expression of Cry1 mRNA in hippocampal formation

CTD
RGD

PMID:15994025 PMID:15994025

NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091

G

cryptochrome circadian regulator 2

decreases expression
decreases expression

Fluoxetine results in decreased expression of CRY2 mRNA
fluoxetine decreases expression of Cry2 mRNA in caudate-putamen

CTD
RGD

PMID:15994025 PMID:15994025

NCBI chr 3:78,374,995...78,405,001
Ensembl chr 3:78,374,995...78,404,965

G

citrate synthase

increases activity
multiple interactions

Fluoxetine results in increased activity of CS protein
[Olanzapine co-treated with Fluoxetine] results in increased activity of CS protein

NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421

G

colony stimulating factor 1 receptor

multiple interactions

[9,10-Dimethyl-1,2-benzanthracene co-treated with Fluoxetine] affects the expression of CSF1R protein; [9,10-Dimethyl-1,2-benzanthracene co-treated with Raloxifene Hydrochloride co-treated with Fluoxetine] affects the expression of CSF1R protein

NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415

G

catenin beta 1

multiple interactions

[Fluoxetine co-treated with Ketanserin] results in increased expression of CTNNB1 mRNA; Fluoxetine inhibits the reaction [Monocrotaline results in decreased expression of CTNNB1 protein]

PMID:21619414 PMID:21627639

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cathepsin K

multiple interactions

Fluoxetine inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]

NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550

G

C-X-C motif chemokine ligand 10

decreases secretion

Fluoxetine results in decreased secretion of CXCL10 protein

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression
multiple interactions

Fluoxetine results in decreased expression of CYP11A1 mRNA
resveratrol inhibits the reaction [Fluoxetine results in decreased expression of CYP11A1 mRNA]

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity

Fluoxetine results in decreased activity of CYP19A1 protein

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Fluoxetine results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 26, subfamily b, polypeptide 1

decreases expression

Fluoxetine results in decreased expression of CYP26B1 mRNA

NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628

G

cytochrome P450, subfamily 2, polypeptide 11

multiple interactions

Fluoxetine inhibits the reaction [CYP2C11 protein results in increased metabolism of 7-methoxy-4-trifluoromethylcoumarin]

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions
decreases activity
increases metabolic processing
affects metabolic processing

Fluoxetine inhibits the reaction [CYP2C6 protein results in increased metabolism of 7-methoxy-4-trifluoromethylcoumarin]
Fluoxetine results in decreased activity of CYP2C19 protein
Fluoxetine inhibits the reaction [CYP2C19 protein results in increased chemical synthesis of 4-hydroxymephenytoin]; Fluoxetine inhibits the reaction [CYP2C19 protein results in increased hydroxylation of Mephenytoin]; Fluoxetine inhibits the reaction [CYP2C19 protein results in increased metabolism of Mephenytoin]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased metabolism of Fluoxetine]
CYP2C19 gene polymorphism affects the metabolism of Fluoxetine; CYP2C19 protein affects the metabolism of Fluoxetine

PMID:11453896 PMID:11752104 PMID:16236141 PMID:19858067 PMID:21915887 More...

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily c, polypeptide 79

decreases activity
multiple interactions

Fluoxetine results in decreased activity of CYP2C8 protein
torsemide inhibits the reaction [Fluoxetine results in decreased activity of CYP2C8 protein]

G

cytochrome P450, family 2, subfamily d, polypeptide 2

multiple interactions

Fluoxetine inhibits the reaction [CYP2D2 protein results in increased metabolism of 3-(2-(N,N-diethyl-N-methylammonium)ethyl)-7-methoxy-4-methylcoumarin]

NCBI chr 7:113,935,138...113,939,209
Ensembl chr 7:113,935,138...113,939,209

G

cytochrome P450, family 2, subfamily d, polypeptide 4

affects abundance
decreases activity
increases metabolic processing
decreases methylation
multiple interactions
affects response to substance
decreases metabolic processing
affects metabolic processing

CYP2D6 gene polymorphism affects the abundance of Fluoxetine; CYP2D6 protein affects the abundance of Fluoxetine
Fluoxetine results in decreased activity of CYP2D6 protein
CYP2D6 protein results in increased metabolism of Fluoxetine
CYP2D22 protein results in increased metabolism of Fluoxetine
CYP2D6 protein results in decreased methylation of Fluoxetine
[Fluoxetine results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; Fluoxetine inhibits the reaction [CYP2D6 protein results in increased metabolism of Tolterodine Tartrate]
CYP2D6 protein affects the susceptibility to Fluoxetine
CYP2D6 gene mutant form results in decreased metabolism of Fluoxetine
CYP2D6 gene polymorphism affects the metabolism of Fluoxetine; CYP2D6 protein affects the metabolism of Fluoxetine

PMID:10583026 PMID:10755579 PMID:12173784 PMID:14639062 PMID:14716707 More...

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases metabolic processing
multiple interactions

CYP3A4 protein results in increased metabolism of Fluoxetine
Fluoxetine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased metabolism of Fluoxetine]

PMID:11752104 PMID:12584149 PMID:16595712

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions

Fluoxetine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

DAB adaptor protein 1

increases expression

Fluoxetine results in increased expression of DAB1 protein

NCBI chr 5:118,392,953...119,513,625
Ensembl chr 5:119,140,533...119,510,552

G

diacylglycerol lipase, beta

multiple interactions

[Fluoxetine affects the susceptibility to Ethanol] which affects the expression of DAGLB mRNA

NCBI chr12:11,059,732...11,102,170
Ensembl chr12:11,059,732...11,102,154

G

death-associated protein

increases expression

Fluoxetine results in increased expression of DAP mRNA

NCBI chr 2:82,199,206...82,251,771
Ensembl chr 2:82,199,280...82,251,752

G

dopamine beta-hydroxylase

multiple interactions
increases expression
increases response to substance

DBH protein promotes the reaction [Fluoxetine results in increased abundance of Serotonin]
Fluoxetine results in increased expression of DBH mRNA
DBH protein results in increased susceptibility to Fluoxetine

PMID:15148402 PMID:20626387

NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248

G

doublecortin-like kinase 1

increases expression

Fluoxetine results in increased expression of DCLK1 mRNA

NCBI chr 2:139,417,234...139,710,956
Ensembl chr 2:139,417,163...139,710,956

G

dendrin

decreases expression

Fluoxetine results in decreased expression of DDN mRNA

NCBI chr 7:129,953,317...129,957,299
Ensembl chr 7:129,953,318...129,957,341

G

DEPP autophagy regulator 1

increases expression

Fluoxetine results in increased expression of DEPP1 mRNA

PMID:15342952 PMID:17175557 PMID:17567588

NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542

G

diacylglycerol O-acyltransferase 1

increases expression

Fluoxetine results in increased expression of DGAT1 mRNA

NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299

G

24-dehydrocholesterol reductase

increases expression

Fluoxetine results in increased expression of DHCR24 mRNA

NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137

G

7-dehydrocholesterol reductase

increases expression

Fluoxetine results in increased expression of DHCR7 mRNA

NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055

G

iodothyronine deiodinase 3

increases activity
increases expression
multiple interactions

Fluoxetine results in increased activity of DIO3 protein
Fluoxetine results in increased expression of DIO3 mRNA
SB 203580 inhibits the reaction [Fluoxetine results in increased expression of DIO3 mRNA]; U 0126 inhibits the reaction [Fluoxetine results in increased activity of DIO3 protein]; U 0126 inhibits the reaction [Fluoxetine results in increased expression of DIO3 mRNA]

NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660

G

DnaJ heat shock protein family (Hsp40) member A2

decreases expression

Fluoxetine results in decreased expression of DNAJA2 mRNA

NCBI chr19:21,497,792...21,516,904
Ensembl chr19:21,497,729...21,516,901

G

DnaJ heat shock protein family (Hsp40) member B9

increases expression

Fluoxetine results in increased expression of DNAJB9 mRNA

NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063

G

dopamine receptor D2

decreases expression
affects expression

Fluoxetine results in decreased expression of DRD2 mRNA
Fluoxetine affects the expression of DRD2

PMID:11981225 PMID:26475043

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dopamine receptor D3

multiple interactions

DRD3 protein results in increased susceptibility to [olanzapine co-treated with Fluoxetine]

NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596

G

dual specificity phosphatase 5

decreases expression

Fluoxetine results in decreased expression of CPG21 mRNA

NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818

G

dual specificity phosphatase 8

increases expression

Fluoxetine results in increased expression of DUSP8 mRNA

NCBI chr 1:197,167,392...197,184,285
Ensembl chr 1:197,169,422...197,182,921

G

EBP, cholestenol delta-isomerase

increases expression

Fluoxetine results in increased expression of EBP mRNA

NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826

G

eukaryotic translation elongation factor 2

increases phosphorylation

Fluoxetine results in increased phosphorylation of EEF2 protein

NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183

G

epidermal growth factor receptor

increases phosphorylation
multiple interactions

Fluoxetine results in increased phosphorylation of EGFR protein
[[Fluoxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; [[Fluoxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Fluoxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Fluoxetine results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Fluoxetine results in increased phosphorylation of EGFR protein]

PMID:18758753 PMID:19662385

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

early growth response 1

multiple interactions
increases expression

[Fluoxetine co-treated with Methylphenidate] results in increased expression of EGR1 mRNA; Fluoxetine promotes the reaction [Methylphenidate results in increased expression of EGR1 mRNA]
Fluoxetine results in increased expression of EGR1 mRNA

PMID:19931852 PMID:21753012

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 3

decreases expression

Fluoxetine results in decreased expression of EGR3 mRNA

NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627

G

early growth response 4

decreases expression

Fluoxetine results in decreased expression of EGR4 mRNA

NCBI chr 4:118,047,869...118,050,328
Ensembl chr 4:118,047,869...118,050,328

G

eukaryotic translation initiation factor 4E

increases phosphorylation

Fluoxetine results in increased phosphorylation of EIF4E protein

NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683

G

ELOVL fatty acid elongase 6

increases expression

Fluoxetine results in increased expression of ELOVL6 mRNA

NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186

G

enamelin

decreases expression

Fluoxetine results in decreased expression of ENAM mRNA

NCBI chr14:19,556,729...19,581,433
Ensembl chr14:19,556,729...19,581,425

G

epoxide hydrolase 4

decreases expression

Fluoxetine results in decreased expression of EPHX4 mRNA

NCBI chr14:2,343,376...2,372,680
Ensembl chr14:2,340,248...2,373,022

G

ergosterol biosynthesis 28 homolog

increases expression

Fluoxetine results in increased expression of ERG28 mRNA

NCBI chr 6:105,474,112...105,483,078
Ensembl chr 6:105,474,113...105,483,078

G

ecotropic viral integration site 2A

increases expression

Fluoxetine results in increased expression of EVI2A mRNA

NCBI chr10:64,485,760...64,489,660
Ensembl chr10:64,485,200...64,489,843

G

fatty acid amide hydrolase

multiple interactions

[Fluoxetine affects the susceptibility to Ethanol] which affects the expression of FAAH mRNA

NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677

G

fatty acid binding protein 1

increases expression

Fluoxetine results in increased expression of FABP1 mRNA

PMID:15342952 PMID:17567588

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

fatty acid binding protein 3

increases expression

Fluoxetine results in increased expression of FABP3 mRNA

NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718

G

fatty acid desaturase 2

increases expression

Fluoxetine results in increased expression of FADS2 mRNA

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

farnesyl diphosphate farnesyl transferase 1

increases expression

Fluoxetine results in increased expression of FDFT1 mRNA

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

fibroblast growth factor 1

increases expression

Fluoxetine results in increased expression of FGF1 mRNA

NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357

G

fibroblast growth factor 2

multiple interactions

[Fluoxetine co-treated with olanzapine] results in increased expression of FGF2 mRNA

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

four and a half LIM domains 2

decreases expression

Fluoxetine results in decreased expression of FHL2 mRNA

NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192

G

folliculin

increases expression

Fluoxetine results in increased expression of FLCN mRNA

NCBI chr10:44,588,621...44,607,808
Ensembl chr10:44,588,624...44,607,769

G

fibromodulin

decreases expression

Fluoxetine results in decreased expression of FMOD mRNA

NCBI chr13:45,493,517...45,504,134
Ensembl chr13:45,493,517...45,504,133

G

fibronectin type III domain containing 4

increases expression

Fluoxetine results in increased expression of FNDC4 mRNA

PMID:15342952 PMID:17175557 PMID:17567588

NCBI chr 6:25,077,155...25,080,812
Ensembl chr 6:25,077,349...25,080,675

G

folliculin interacting protein 1

increases expression

Fluoxetine results in increased expression of FNIP1 mRNA

NCBI chr10:38,567,728...38,650,824
Ensembl chr10:38,567,729...38,650,824

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression
affects expression
decreases expression

[Fluoxetine co-treated with Methylphenidate] results in increased expression of FOS mRNA; [Fluoxetine co-treated with Olanzapine] results in decreased expression of FOS protein; Fluoxetine inhibits the reaction [Fenfluramine results in increased expression of FOS protein]; Fluoxetine promotes the reaction [Methylphenidate results in increased expression of FOS mRNA]; SB 206553 inhibits the reaction [Fluoxetine results in increased expression of FOS protein]
Fluoxetine results in increased expression of FOS mRNA; Fluoxetine results in increased expression of FOS protein
Fluoxetine affects the expression of FOS protein
Fluoxetine results in decreased expression of FOS mRNA
N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Fluoxetine results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of FOS mRNA]; U 0126 inhibits the reaction [Fluoxetine results in increased expression of FOS mRNA]; U 0126 inhibits the reaction [Fluoxetine results in increased expression of FOS protein]

PMID:9452197 PMID:9740405 PMID:12527473 PMID:14556240 PMID:15609068 More...

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FosB proto-oncogene, AP-1 transcription factor subunit

increases expression
multiple interactions

Fluoxetine results in increased expression of FOSB mRNA; Fluoxetine results in increased expression of FOSB protein
N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Fluoxetine results in increased expression of FOSB mRNA]; RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of FOSB mRNA]; RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of FOSB protein]; U 0126 inhibits the reaction [Fluoxetine results in increased expression of FOSB mRNA]; U 0126 inhibits the reaction [Fluoxetine results in increased expression of FOSB protein]

NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465

G

glucose-6-phosphatase catalytic subunit 1

decreases expression
multiple interactions

Fluoxetine results in decreased expression of G6PC1 protein
[Fluoxetine results in decreased expression of G6PC1 protein] which results in increased abundance of Acetyl Coenzyme A; [Fluoxetine results in decreased expression of G6PC1 protein] which results in increased abundance of Glucose-6-Phosphate

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

gamma-aminobutyric acid type A receptor subunit delta

decreases expression

Fluoxetine results in decreased expression of GABRD mRNA

NCBI chr 5:165,958,508...165,970,407
Ensembl chr 5:165,958,484...165,970,411

G

glutamate decarboxylase 1

increases expression

Fluoxetine results in increased expression of GAD1 mRNA

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

glutamate decarboxylase 2

increases expression
decreases expression

Fluoxetine results in increased expression of GAD2 protein
Fluoxetine results in decreased expression of GAD2 mRNA

PMID:9526047 PMID:19359144

NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155

G

cyclin G associated kinase

decreases expression

Fluoxetine results in decreased expression of GAK mRNA

NCBI chr14:1,089,853...1,164,098
Ensembl chr14:1,089,866...1,216,398

G

galanin and GMAP prepropeptide

increases expression

Fluoxetine results in increased expression of GAL mRNA

NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959

G

polypeptide N-acetylgalactosaminyltransferase 11

increases expression

Fluoxetine results in increased expression of GALNT11 mRNA

NCBI chr 4:9,837,629...9,871,141
Ensembl chr 4:9,837,629...9,871,140

G

galanin receptor 1

increases expression

fluoxetine co-treated with chronic restraint stress increases expression of Galr1 mRNA in nucleus accumbens

RGD

NCBI chr18:75,772,021...75,787,577
Ensembl chr18:75,772,023...75,787,577

G

galanin receptor 2

increases expression

fluoxetine co-treated with chronic restraint stress increases expression of Galr2 mRNA in nucleus accumbens

RGD

NCBI chr10:101,513,689...101,517,176
Ensembl chr10:101,514,471...101,517,176

G

growth associated protein 43

decreases expression

Fluoxetine results in decreased expression of GAP43 mRNA

NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045

G

glial cell derived neurotrophic factor

increases expression
multiple interactions

Fluoxetine results in increased expression of GDNF mRNA
U 0126 inhibits the reaction [Fluoxetine results in increased expression of GDNF mRNA]

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

glycerophosphodiester phosphodiesterase domain containing 3

increases expression

Fluoxetine results in increased expression of GDPD3 mRNA

PMID:17175557 PMID:17567588

NCBI chr 1:181,373,505...181,383,063
Ensembl chr 1:181,366,626...181,383,063

G

glial fibrillary acidic protein

increases response to substance
increases expression

GFAP protein results in increased susceptibility to Fluoxetine
Fluoxetine results in increased expression of GFAP mRNA; Fluoxetine results in increased expression of GFAP protein

PMID:20857517 PMID:22113448

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

gap junction protein, alpha 1

increases expression

Fluoxetine results in increased expression of GJA1 protein

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

glyoxalase 1

increases response to substance

GLO1 protein results in increased susceptibility to Fluoxetine

NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649

G

G protein subunit alpha 11

multiple interactions
decreases expression

Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Fluoxetine results in decreased expression of GNA11 protein]

NCBI chr 7:8,163,520...8,177,863
Ensembl chr 7:8,162,750...8,179,812

G

G protein subunit alpha 12

increases expression

Fluoxetine results in increased expression of GNA12 mRNA

NCBI chr12:13,805,580...13,886,255
Ensembl chr12:13,805,698...13,886,255

G

G protein subunit alpha i2

decreases expression
multiple interactions

Fluoxetine results in decreased expression of GNAI2 mRNA
Fluoxetine inhibits the reaction [Corticosterone results in decreased expression of GNAI2 mRNA]

PMID:19477151 PMID:21852994

NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979

G

G protein subunit alpha q

increases expression
decreases expression
multiple interactions

Fluoxetine results in increased expression of GNAQ mRNA
Fluoxetine results in decreased expression of GNAQ protein
Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Fluoxetine results in decreased expression of GNAQ protein]

PMID:1426031 PMID:21712787

NCBI chr 1:213,425,631...213,671,947
Ensembl chr 1:213,424,465...213,667,672

G

GNAS complex locus

increases expression
decreases expression

Fluoxetine results in increased expression of GNAS mRNA
Fluoxetine results in decreased expression of GNAS mRNA

PMID:1426031 PMID:21852994

NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262

G

G protein subunit beta 2

decreases expression

Fluoxetine results in decreased expression of GNB2 mRNA

NCBI chr12:19,159,002...19,164,021
Ensembl chr12:19,158,973...19,164,019

G

G patch domain containing 4

increases expression

Fluoxetine results in increased expression of GPATCH4 mRNA

NCBI chr 2:173,499,700...173,520,346
Ensembl chr 2:173,509,897...173,518,684

G

glycerol-3-phosphate dehydrogenase 1

increases expression

Fluoxetine results in increased expression of GPD1 mRNA

NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529

G

glutamic--pyruvic transaminase

increases expression
multiple interactions

Fluoxetine results in increased expression of GPT protein
vinpocetine inhibits the reaction [Fluoxetine results in increased expression of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 3

increases expression

Fluoxetine results in increased expression of GPX3 mRNA

NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035

G

GRAM domain containing 2B

increases expression

Fluoxetine results in increased expression of GRAMD2B mRNA

NCBI chr18:49,884,014...49,981,955
Ensembl chr18:49,884,014...49,981,953

G

glutamate ionotropic receptor AMPA type subunit 1

affects expression
multiple interactions
affects phosphorylation

Fluoxetine affects the expression of GRIA1 protein
PPP1R1B protein promotes the reaction [Fluoxetine affects the phosphorylation of GRIA1 protein]

PMID:11880651 PMID:20417256

NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283

G

glutamate ionotropic receptor AMPA type subunit 2

increases expression
multiple interactions

Fluoxetine results in increased expression of GRIA2 protein
[Fluoxetine affects the susceptibility to Ethanol] which affects the expression of GRIA2 mRNA

PMID:20417256 PMID:31339221

NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510

G

glutamate ionotropic receptor AMPA type subunit 4

multiple interactions

[Fluoxetine affects the susceptibility to Ethanol] which affects the expression of GRIA4 mRNA

NCBI chr 8:1,562,118...2,035,035
Ensembl chr 8:1,562,119...2,034,979

G

glutamate ionotropic receptor kainate type subunit 2

multiple interactions
increases expression

ADARB1 protein promotes the reaction [Fluoxetine results in increased expression of GRIK2 mRNA]; ADARB1 protein promotes the reaction [Fluoxetine results in increased expression of GRIK2 protein]; HTR2B protein promotes the reaction [Fluoxetine results in increased expression of GRIK2 mRNA]; HTR2B protein promotes the reaction [Fluoxetine results in increased expression of GRIK2 protein]
Fluoxetine results in increased expression of GRIK2 mRNA; Fluoxetine results in increased expression of GRIK2 protein

NCBI chr20:52,135,325...52,833,061
Ensembl chr20:52,133,851...52,838,375

G

glutamate ionotropic receptor NMDA type subunit 2A

increases expression

Fluoxetine results in increased expression of GRIN2A protein

NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637

G

glutamate metabotropic receptor 3

multiple interactions

[Fluoxetine affects the susceptibility to Ethanol] which affects the expression of GRM3 mRNA

NCBI chr 4:24,364,854...24,643,972
Ensembl chr 4:24,365,115...24,609,804

G

glycogen synthase kinase 3 beta

increases expression

Fluoxetine results in increased expression of GSK3B protein

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

hyaluronan and proteoglycan link protein 2

decreases expression

Fluoxetine results in decreased expression of HAPLN2 mRNA

NCBI chr 2:173,488,909...173,496,824
Ensembl chr 2:173,491,160...173,496,588

G

histone deacetylase 2

increases expression
multiple interactions

Fluoxetine results in increased expression of HDAC2 mRNA; Fluoxetine results in increased expression of HDAC2 protein
Fluoxetine affects the reaction [sodium arsenate affects the expression of HDAC2 protein]

PMID:16670375 PMID:24952232

NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609

G

histone deacetylase 5

increases response to substance

HDAC5 protein results in increased susceptibility to Fluoxetine

NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235

G

hes family bHLH transcription factor 1

increases expression

Fluoxetine results in increased expression of HES1 mRNA; Fluoxetine results in increased expression of HES1 protein

NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192

G

hes family bHLH transcription factor 5

increases expression

Fluoxetine results in increased expression of HES5 mRNA; Fluoxetine results in increased expression of HES5 protein

PMID:17033635 PMID:19801843

NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001

G

hes family bHLH transcription factor 7

affects expression

Fluoxetine affects the expression of HES7 mRNA

NCBI chr10:53,824,124...53,828,934
Ensembl chr10:53,825,574...53,828,097

G

hypoxia inducible factor 1 subunit alpha

increases expression

Fluoxetine results in increased expression of HIF1A mRNA

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases expression

Fluoxetine results in increased expression of HMGCR mRNA

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

increases expression

Fluoxetine results in increased expression of HMGCS1 mRNA

PMID:16324787 PMID:37386098

NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100

G

heme oxygenase 1

multiple interactions
increases expression

Fluoxetine inhibits the reaction [Lipopolysaccharides results in decreased expression of HMOX1 protein]
vinpocetine inhibits the reaction [Fluoxetine results in increased expression of HMOX1 protein]

PMID:34669537 PMID:36169195

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

homer scaffold protein 1

decreases expression

Fluoxetine results in decreased expression of HOMER1 mRNA

NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785

G

homeo box C6

affects expression

Fluoxetine affects the expression of HOXC6 mRNA

NCBI chr 7:134,138,017...134,148,899
Ensembl chr 7:134,135,502...134,148,392

G

hippocalcin-like 1

increases expression

Fluoxetine results in increased expression of HPCAL1 mRNA

NCBI chr 6:40,478,206...40,584,721
Ensembl chr 6:40,478,208...40,584,687

G

hepsin

increases expression

Fluoxetine results in increased expression of HPN mRNA

NCBI chr 1:86,337,085...86,352,785
Ensembl chr 1:86,337,087...86,352,811

G

hemopexin

decreases expression

Fluoxetine results in decreased expression of HPX mRNA

NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328

G

histamine receptor H 1

multiple interactions

HRH1 protein results in increased susceptibility to [olanzapine co-treated with Fluoxetine]

NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455

G

hydroxysteroid (17-beta) dehydrogenase 14

increases expression

Fluoxetine results in increased expression of HSD17B14 mRNA

NCBI chr 1:96,029,224...96,039,577
Ensembl chr 1:96,029,284...96,039,883

G

hydroxysteroid (17-beta) dehydrogenase 7

increases expression

Fluoxetine results in increased expression of HSD17B7 mRNA

NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017

G

heat shock protein family B (small) member 8

increases expression

Fluoxetine results in increased expression of HSPB8 mRNA

NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185

G

5-hydroxytryptamine receptor 1A

multiple interactions
affects expression
decreases expression
increases response to substance
affects response to substance
increases expression

Fluoxetine inhibits the reaction [IFNA1 protein results in decreased expression of HTR1A mRNA]; Fluoxetine inhibits the reaction [IFNA1 protein results in decreased expression of HTR1A protein]
Fluoxetine affects the expression of HTR1A
Fluoxetine results in decreased expression of HTR1A mRNA
HTR1A gene polymorphism results in increased susceptibility to Fluoxetine; HTR1A protein results in increased susceptibility to Fluoxetine
HTR1A promoter polymorphism affects the susceptibility to Fluoxetine
Fluoxetine inhibits the reaction [8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein]; Fluoxetine inhibits the reaction [HTR1A protein results in increased uptake of Serotonin]; N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide inhibits the reaction [HTR1A protein results in increased susceptibility to Fluoxetine]; N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide promotes the reaction [Fluoxetine inhibits the reaction [HTR1A protein results in increased uptake of Serotonin]]
Fluoxetine results in increased expression of HTR1A mRNA

PMID:10665824 PMID:11106871 PMID:15885359 PMID:16302021 PMID:16458487 More...

NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442

G

5-hydroxytryptamine receptor 1B

decreases expression
increases expression

Fluoxetine results in decreased expression of HTR1B mRNA
Fluoxetine results in increased expression of HTR1B mRNA

PMID:8914125 PMID:10665824 PMID:10861803

NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549

G

5-hydroxytryptamine receptor 2A

affects response to substance
affects expression
decreases activity
increases expression

HTR2A protein affects the susceptibility to Fluoxetine
Fluoxetine affects the expression of HTR2A
Fluoxetine results in decreased activity of HTR2A protein
Fluoxetine results in increased expression of HTR2A mRNA

PMID:10773209 PMID:19445393 PMID:20464512 PMID:21083617 PMID:26475043

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

G

5-hydroxytryptamine receptor 2B

increases expression
increases activity
multiple interactions

Fluoxetine results in increased expression of HTR2B mRNA
Fluoxetine results in increased activity of HTR2B protein
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; [[Fluoxetine binds to and results in increased activity of HTR2B protein] which results in increased activity of MAPK1 protein] which results in increased expression of PLA2G4A protein; [[Fluoxetine binds to and results in increased activity of HTR2B protein] which results in increased activity of MAPK3 protein] which results in increased expression of PLA2G4A protein; [Fluoxetine binds to and results in increased activity of HTR2B protein] which results in increased activity of MAPK1 protein; [Fluoxetine binds to and results in increased activity of HTR2B protein] which results in increased activity of MAPK3 protein; [Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein; [Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein; [Fluoxetine results in increased expression of and results in increased activity of HTR2B protein] which results in increased metabolism of Glycogen; bisindolylmaleimide I inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; bisindolylmaleimide I inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; Calcium promotes the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; Calcium promotes the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; Fluoxetine binds to and results in increased activity of HTR2B protein; Fluoxetine promotes the reaction [mesulergine binds to HTR2B protein]; Fluoxetine results in increased expression of and results in increased activity of HTR2B protein; HTR2B protein inhibits the reaction [Fluoxetine inhibits the reaction [Excitatory Amino Acid Agents results in increased phosphorylation of MAPK1 protein]]; HTR2B protein inhibits the reaction [Fluoxetine inhibits the reaction [Excitatory Amino Acid Agents results in increased phosphorylation of MAPK3 protein]]; HTR2B protein promotes the reaction [Fluoxetine results in increased expression of ADARB1 mRNA]; HTR2B protein promotes the reaction [Fluoxetine results in increased expression of ADARB1 protein]; HTR2B protein promotes the reaction [Fluoxetine results in increased expression of GRIK2 mRNA]; HTR2B protein promotes the reaction [Fluoxetine results in increased expression of GRIK2 protein]; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea promotes the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea promotes the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]

PMID:11930908 PMID:18758753 PMID:19662385 PMID:21083617 PMID:21320410

NCBI chr 9:86,735,793...86,756,638
Ensembl chr 9:86,742,102...86,755,108

G

5-hydroxytryptamine receptor 2C

affects binding
multiple interactions
increases expression

Fluoxetine binds to HTR2C protein
[[Fluoxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; [[Fluoxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Fluoxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein; Fluoxetine binds to and results in increased activity of HTR2C protein
[Fluoxetine results in increased abundance of Serotonin] which results in decreased expression of HTR2C mRNA; Fluoxetine binds to and results in decreased activity of HTR2C protein; Fluoxetine inhibits the reaction [Serotonin binds to and results in increased activity of HTR2C protein]
Fluoxetine results in increased expression of HTR2C mRNA; Fluoxetine results in increased expression of HTR2C mRNA alternative form

PMID:9050900 PMID:15659601 PMID:18083778 PMID:19662385 PMID:21083617 More...

NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287

G

intercellular adhesion molecule 5

decreases expression

Fluoxetine results in decreased expression of ICAM5 mRNA

NCBI chr 8:19,567,390...19,575,588
Ensembl chr 8:19,568,600...19,575,588

G

isopentenyl-diphosphate delta isomerase 1

increases expression

Fluoxetine results in increased expression of IDI1 mRNA

NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357

G

interferon, alpha 1

multiple interactions

Fluoxetine inhibits the reaction [IFNA1 protein results in decreased expression of HTR1A mRNA]; Fluoxetine inhibits the reaction [IFNA1 protein results in decreased expression of HTR1A protein]; Fluoxetine inhibits the reaction [IFNA1 protein results in decreased expression of NR3C1 mRNA]; Fluoxetine inhibits the reaction [IFNA1 protein results in decreased expression of NR3C1 protein]

NCBI chr 5:103,097,356...103,097,925
Ensembl chr 5:103,097,356...103,097,925

G

interferon gamma

increases expression

Fluoxetine results in increased expression of IFNG mRNA

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 2

decreases expression

Fluoxetine results in decreased expression of IGF2 mRNA

NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018

G

insulin-like growth factor binding protein 2

decreases expression

Fluoxetine results in decreased expression of IGFBP2 mRNA

NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937

G

interleukin 1 beta

decreases expression
multiple interactions

Fluoxetine results in decreased expression of IL1B mRNA
Fluoxetine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]

PMID:21966942 PMID:36169195

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions
increases expression

Fluoxetine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Fluoxetine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Fluoxetine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
vinpocetine inhibits the reaction [Fluoxetine results in increased expression of IL6 protein]
Fluoxetine results in increased expression of IL6 mRNA

PMID:16413968 PMID:21575647 PMID:34669537 PMID:36169195

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inhibin subunit beta E

increases expression

Fluoxetine results in increased expression of INHBE mRNA

PMID:15342952 PMID:17175557 PMID:17567588

NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172

G

insulin induced gene 1

increases expression

Fluoxetine results in increased expression of INSIG1 mRNA

PMID:21852994 PMID:37386098

NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952

G

integrin subunit alpha M

multiple interactions

Fluoxetine inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAM protein]

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

inositol-trisphosphate 3-kinase A

decreases expression

Fluoxetine results in decreased expression of ITPKA mRNA

NCBI chr 3:106,726,036...106,734,601
Ensembl chr 3:106,726,036...106,734,600

G

jagged canonical Notch ligand 1

increases expression

Fluoxetine results in increased expression of JAG1 mRNA; Fluoxetine results in increased expression of JAG1 protein

NCBI chr 3:124,406,783...124,442,220
Ensembl chr 3:124,406,794...124,442,209

G

Jun proto-oncogene, AP-1 transcription factor subunit

decreases expression

Fluoxetine results in decreased expression of JUN mRNA

PMID:17105902 PMID:18836303

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

potassium voltage-gated channel subfamily A member 3

decreases activity

Fluoxetine results in decreased activity of KCNA3 protein

NCBI chr 2:194,632,106...194,634,059
Ensembl chr 2:194,632,196...194,650,138

G

potassium voltage-gated channel subfamily A member 5

increases expression

Fluoxetine results in increased expression of KCNA5 mRNA; Fluoxetine results in increased expression of KCNA5 protein

NCBI chr 4:159,354,689...159,358,173
Ensembl chr 4:159,350,097...159,357,697

G

potassium voltage-gated channel subfamily A member 6

decreases expression

Fluoxetine results in decreased expression of KCNA6 mRNA

NCBI chr 4:159,542,941...159,576,189
Ensembl chr 4:159,542,615...159,576,189

G

potassium voltage-gated channel subfamily D member 3

decreases activity

Fluoxetine results in decreased activity of KCND3 protein

NCBI chr 2:192,937,950...193,155,345
Ensembl chr 2:192,937,950...193,155,345

G

potassium voltage-gated channel subfamily H member 2

multiple interactions
decreases expression
decreases activity
affects response to substance
affects localization

Fluoxetine binds to and results in decreased activity of KCNH2 protein; Fluoxetine inhibits the reaction [KCNH2 protein results in increased transport of Potassium]; Fluoxetine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]
Fluoxetine results in decreased expression of KCNH2 protein modified form
Fluoxetine results in decreased activity of KCNH2 protein
KCNH2 protein affects the susceptibility to Fluoxetine
Fluoxetine affects the localization of KCNH2 protein

PMID:11805215 PMID:15272206 PMID:16967046 PMID:21158687 PMID:24052561 More...

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

potassium inwardly-rectifying channel, subfamily J, member 3

multiple interactions

Fluoxetine inhibits the reaction [[KCNJ3 protein co-treated with KCNJ5 protein] results in increased transport of Potassium]; Fluoxetine inhibits the reaction [[KCNJ3 protein co-treated with KCNJ6 protein] results in increased transport of Potassium]

NCBI chr 3:39,944,896...40,106,646
Ensembl chr 3:39,945,351...40,109,124

G

potassium inwardly-rectifying channel, subfamily J, member 4

multiple interactions

Fluoxetine inhibits the reaction [Methamphetamine results in decreased expression of KCNJ4 mRNA]

NCBI chr 7:111,047,097...111,074,151
Ensembl chr 7:111,047,094...111,074,151

G

potassium inwardly-rectifying channel, subfamily J, member 5

multiple interactions

Fluoxetine inhibits the reaction [[KCNJ3 protein co-treated with KCNJ5 protein] results in increased transport of Potassium]

NCBI chr 8:30,724,923...30,753,083
Ensembl chr 8:30,724,925...30,753,518

G

potassium inwardly-rectifying channel, subfamily J, member 6

multiple interactions

Fluoxetine inhibits the reaction [[KCNJ3 protein co-treated with KCNJ6 protein] results in increased transport of Potassium]; Fluoxetine inhibits the reaction [KCNJ6 protein results in increased transport of Potassium]

NCBI chr11:34,061,702...34,308,758
Ensembl chr11:34,061,708...34,308,758

G

potassium two pore domain channel subfamily K member 10

decreases activity
affects response to substance
multiple interactions
increases expression

Fluoxetine results in decreased activity of KCNK10 protein
KCNK10 mRNA affects the susceptibility to Fluoxetine
[KCNK2 mRNA co-treated with KCNK10 mRNA] affects the susceptibility to Fluoxetine
Fluoxetine results in increased expression of KCNK10 mRNA

NCBI chr 6:117,690,052...117,826,120
Ensembl chr 6:117,694,222...117,825,695

G

potassium two pore domain channel subfamily K member 2

multiple interactions
decreases activity
affects response to substance
decreases expression
decreases response to substance

Fluoxetine inhibits the reaction [Dexamethasone results in increased expression of KCNK2 mRNA]; Fluoxetine inhibits the reaction [Dexamethasone results in increased expression of KCNK2 protein]
[KCNK2 mRNA co-treated with KCNK10 mRNA] affects the susceptibility to Fluoxetine
Fluoxetine results in decreased activity of KCNK2 protein
KCNK2 mRNA affects the susceptibility to Fluoxetine
Fluoxetine results in decreased expression of KCNK2 mRNA
Fluoxetine results in decreased susceptibility to KCNK2 protein
Fluoxetine results in decreased expression of KCNK2 mRNA; Fluoxetine results in decreased expression of KCNK2 protein

PMID:21069514 PMID:23022515

NCBI chr13:100,766,101...100,963,435
Ensembl chr13:100,766,113...100,963,435

G

potassium voltage-gated channel modifier subfamily V member 1

decreases expression

Fluoxetine results in decreased expression of KCNV1 mRNA

NCBI chr 7:76,260,695...76,269,170
Ensembl chr 7:76,260,695...76,269,170

G

KLF transcription factor 10

increases expression

Fluoxetine results in increased expression of KLF10 mRNA

NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994

G

kelch-like family member 24

increases expression

Fluoxetine results in increased expression of KLHL24 mRNA

NCBI chr11:80,843,621...80,877,649
Ensembl chr11:80,846,755...80,877,636

G

L1 cell adhesion molecule

multiple interactions
increases expression

Ondansetron inhibits the reaction [Fluoxetine results in increased expression of L1CAM protein]

NCBI chr X:151,597,270...151,623,776
Ensembl chr X:151,597,277...151,623,857

G

lamin A/C

decreases expression

Fluoxetine results in decreased expression of LMNA mRNA

NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423

G

LON peptidase N-terminal domain and ring finger 1

increases expression

Fluoxetine results in increased expression of LONRF1 mRNA

NCBI chr16:55,984,572...56,015,156
Ensembl chr16:55,984,463...56,015,156

G

lipin 1

increases expression

Fluoxetine results in increased expression of LPIN1 mRNA

NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097

G

leucine-rich alpha-2-glycoprotein 1

increases expression

Fluoxetine results in increased expression of LRG1 mRNA

NCBI chr 9:947,516...949,773
Ensembl chr 9:947,516...949,813

G

lanosterol synthase

increases expression

Fluoxetine results in increased expression of LSS mRNA

PMID:15342952 PMID:17567588 PMID:37386098

NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762

G

microtubule-associated protein 1B

increases expression

Fluoxetine results in increased expression of MAP1B mRNA

NCBI chr 2:30,817,261...30,910,458
Ensembl chr 2:30,817,261...30,910,317

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation
increases expression
decreases phosphorylation
decreases expression

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; [[Fluoxetine binds to and results in increased activity of HTR2B protein] which results in increased activity of MAPK1 protein] which results in increased expression of PLA2G4A protein; [[Fluoxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; [Fluoxetine binds to and results in increased activity of HTR2B protein] which results in increased activity of MAPK1 protein; [Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein; ADARB1 protein inhibits the reaction [Fluoxetine inhibits the reaction [Excitatory Amino Acid Agents results in increased phosphorylation of MAPK1 protein]]; bisindolylmaleimide I inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; Calcium promotes the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; Fluoxetine inhibits the reaction [Excitatory Amino Acid Agents results in increased phosphorylation of MAPK1 protein]; HTR2B protein inhibits the reaction [Fluoxetine inhibits the reaction [Excitatory Amino Acid Agents results in increased phosphorylation of MAPK1 protein]]; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea promotes the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]
Fluoxetine results in increased phosphorylation of MAPK1 protein
Fluoxetine results in increased expression of MAPK1 protein
Fluoxetine results in decreased phosphorylation of MAPK1 protein
Fluoxetine results in decreased expression of MAPK1 mRNA
[Fluoxetine co-treated with Methylphenidate] results in increased expression of MAPK1 mRNA; [Fluoxetine co-treated with Methylphenidate] results in increased phosphorylation of MAPK1 protein; Fluoxetine results in increased phosphorylation of and results in increased activity of MAPK1 protein; N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide inhibits the reaction [Fluoxetine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [Fluoxetine results in increased phosphorylation of and results in increased activity of MAPK1 protein]

PMID:15138445 PMID:15456934 PMID:16413968 PMID:18573488 PMID:18758753 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

increases phosphorylation

Fluoxetine results in increased phosphorylation of MAPK14 protein

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation
increases expression
decreases phosphorylation

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; [[Fluoxetine binds to and results in increased activity of HTR2B protein] which results in increased activity of MAPK3 protein] which results in increased expression of PLA2G4A protein; [[Fluoxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Fluoxetine binds to and results in increased activity of HTR2B protein] which results in increased activity of MAPK3 protein; [Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein; ADARB1 protein inhibits the reaction [Fluoxetine inhibits the reaction [Excitatory Amino Acid Agents results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Fluoxetine results in increased expression of MAPK3 protein]; bisindolylmaleimide I inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; Calcium promotes the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; Fluoxetine inhibits the reaction [Excitatory Amino Acid Agents results in increased phosphorylation of MAPK3 protein]; HTR2B protein inhibits the reaction [Fluoxetine inhibits the reaction [Excitatory Amino Acid Agents results in increased phosphorylation of MAPK3 protein]]; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea promotes the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]
Fluoxetine results in increased phosphorylation of MAPK3 protein
Fluoxetine results in increased phosphorylation of and results in increased activity of MAPK3 protein; N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide inhibits the reaction [Fluoxetine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [Fluoxetine results in increased phosphorylation of and results in increased activity of MAPK3 protein]
Fluoxetine results in decreased phosphorylation of MAPK3 protein

PMID:15138445 PMID:15456934 PMID:16413968 PMID:18573488 PMID:18758753 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

decreases expression

Fluoxetine results in decreased expression of MAPK8 mRNA

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

methyl-CpG binding domain protein 1

increases expression

Fluoxetine results in increased expression of MBD1 mRNA; Fluoxetine results in increased expression of MBD1 protein

NCBI chr18:67,869,870...67,884,501
Ensembl chr18:67,869,992...67,886,554

G

melanocortin 4 receptor

decreases expression

Fluoxetine results in decreased expression of MC4R mRNA; Fluoxetine results in decreased expression of MC4R protein

NCBI chr18:60,419,832...60,421,719
Ensembl chr18:60,419,832...60,421,719

G

methyl CpG binding protein 2

increases expression

Fluoxetine results in increased expression of MECP2 mRNA; Fluoxetine results in increased expression of MECP2 mRNA alternative form; Fluoxetine results in increased expression of MECP2 protein

NCBI chr X:151,781,177...151,844,687
Ensembl chr X:151,789,930...151,844,689

G

mesenchyme homeobox 1

affects expression

Fluoxetine affects the expression of MEOX1 mRNA

NCBI chr10:86,818,450...86,837,563
Ensembl chr10:86,818,478...86,837,660

G

macrophage migration inhibitory factor

affects response to substance

MIF affects the susceptibility to Fluoxetine

NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504

G

Mix paired-like homeobox 1

affects expression

Fluoxetine affects the expression of MIXL1 mRNA

NCBI chr13:92,422,031...92,426,065
Ensembl chr13:92,422,031...92,426,065

G

matrix metallopeptidase 20

decreases expression

Fluoxetine results in decreased expression of MMP20 mRNA

NCBI chr 8:4,789,415...4,830,035
Ensembl chr 8:4,789,415...4,830,035

G

matrix metallopeptidase 9

multiple interactions
decreases activity

Fluoxetine inhibits the reaction [TNFSF11 protein results in increased expression of MMP9 mRNA]
[9,10-Dimethyl-1,2-benzanthracene co-treated with Raloxifene Hydrochloride co-treated with Fluoxetine] affects the expression of MMP9 protein
Fluoxetine results in decreased activity of MMP9 protein

PMID:15312242 PMID:21966942 PMID:31332895

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

methylsterol monooxygenase 1

increases expression

Fluoxetine results in increased expression of MSMO1 mRNA

NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016

G

mitochondrial fission regulator 1

increases expression

Fluoxetine results in increased expression of MTFR1 mRNA

NCBI chr 2:101,678,331...101,713,547
Ensembl chr 2:101,679,265...101,713,544

G

mechanistic target of rapamycin kinase

multiple interactions

[Fluoxetine co-treated with Methylphenidate] results in increased expression of MTOR mRNA; [Fluoxetine co-treated with Methylphenidate] results in increased phosphorylation of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

mevalonate kinase

increases expression

Fluoxetine results in increased expression of MVK mRNA

NCBI chr12:42,141,391...42,158,893
Ensembl chr12:42,141,384...42,158,882

G

MYC proto-oncogene, bHLH transcription factor

decreases phosphorylation

Fluoxetine results in decreased phosphorylation of MYC protein

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

Nanog homeobox

affects expression

Fluoxetine affects the expression of NANOG mRNA

NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116

G

N-acyl phosphatidylethanolamine phospholipase D

multiple interactions

[Fluoxetine affects the susceptibility to Ethanol] which affects the expression of NAPEPLD mRNA

NCBI chr 4:13,360,532...13,398,815
Ensembl chr 4:13,361,006...13,398,748

G

neural cell adhesion molecule 1

increases expression

Fluoxetine results in increased expression of NCAM1 mRNA

NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014

G

neuraminidase 1

increases expression

Fluoxetine results in increased expression of NEU1 mRNA

NCBI chr20:3,897,480...3,901,745
Ensembl chr20:3,897,480...3,901,745

G

neuronal differentiation 2

decreases expression

Fluoxetine results in decreased expression of NEUROD2 mRNA

NCBI chr10:83,323,801...83,327,986
Ensembl chr10:83,324,442...83,327,986

G

neurofibromin 1

decreases expression

Fluoxetine results in decreased expression of NF1 mRNA

NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658

G

NFE2 like bZIP transcription factor 2

multiple interactions
increases expression

Fluoxetine inhibits the reaction [Lipopolysaccharides results in decreased expression of NFE2L2 protein]
vinpocetine inhibits the reaction [Fluoxetine results in increased expression of NFE2L2 protein]

PMID:34669537 PMID:36169195

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NFKB inhibitor alpha

multiple interactions
increases expression

Fluoxetine inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]
Fluoxetine results in increased expression of NFKBIA mRNA

PMID:17033635 PMID:21575647

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nerve growth factor receptor

increases response to substance

NGFR protein results in increased susceptibility to Fluoxetine

NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518

G

nodal growth differentiation factor

affects expression

Fluoxetine affects the expression of NODAL mRNA

NCBI chr20:29,368,436...29,376,837
Ensembl chr20:29,368,436...29,376,837

G

nitric oxide synthase 2

multiple interactions
increases expression

Fluoxetine analog inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; Fluoxetine analog inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Fluoxetine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Fluoxetine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
Fluoxetine results in increased expression of NOS2 mRNA

PMID:16413968 PMID:21467642 PMID:21575647

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

notch receptor 1

increases expression

Fluoxetine results in increased expression of NOTCH1 mRNA; Fluoxetine results in increased expression of NOTCH1 protein

NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531

G

neuronal PAS domain protein 2

affects expression

Fluoxetine affects the expression of NPAS2 mRNA

NCBI chr 9:41,463,361...41,642,322
Ensembl chr 9:41,463,830...41,642,320

G

neuronal pentraxin 2

increases expression

Fluoxetine results in increased expression of NPTX2 mRNA

NCBI chr12:10,037,435...10,048,345
Ensembl chr12:10,037,435...10,048,345

G

neuropeptide Y

increases expression
decreases secretion
affects expression
decreases expression

Fluoxetine results in increased expression of NPY mRNA
Fluoxetine results in decreased secretion of NPY mRNA; Fluoxetine results in decreased secretion of NPY protein
Fluoxetine affects the expression of NPY mRNA
Fluoxetine results in decreased expression of NPY mRNA

PMID:8737424 PMID:9729278 PMID:16042082 PMID:20816900

NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495

G

neuropeptide Y receptor Y1

affects expression

Fluoxetine affects the expression of NPY1R mRNA

NCBI chr16:23,037,788...23,047,330
Ensembl chr16:23,037,789...23,046,759

G

nuclear receptor subfamily 0, group B, member 2

increases expression

Fluoxetine results in increased expression of NR0B2 mRNA

PMID:15342952 PMID:17175557

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions
affects expression
decreases expression
increases expression
affects response to substance

Fluoxetine inhibits the reaction [IFNA1 protein results in decreased expression of NR3C1 mRNA]; Fluoxetine inhibits the reaction [IFNA1 protein results in decreased expression of NR3C1 protein]
Fluoxetine affects the expression of NR3C1 protein
Fluoxetine affects the reaction [sodium arsenate affects the expression of NR3C1 protein]; Fluoxetine promotes the reaction [Dexamethasone results in increased activity of NR3C1 protein]; Fluoxetine promotes the reaction [Hydrocortisone results in increased activity of NR3C1 protein]
Fluoxetine results in decreased expression of NR3C1 mRNA
Fluoxetine results in increased expression of NR3C1 mRNA; Fluoxetine results in increased expression of NR3C1 protein
NR3C1 protein affects the susceptibility to Fluoxetine

PMID:10929085 PMID:11226678 PMID:11406320 PMID:12393271 PMID:12871829 More...

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

nuclear receptor subfamily 3, group C, member 2

decreases expression
increases expression
multiple interactions

Fluoxetine results in decreased expression of NR3C2 mRNA
Fluoxetine results in increased expression of NR3C2 mRNA; Fluoxetine results in increased expression of NR3C2 protein
Fluoxetine affects the reaction [Dexamethasone binds to NR3C2 protein]

PMID:1351783 PMID:10929085 PMID:11406320 PMID:12393271 PMID:21281618

NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885

G

nuclear receptor subfamily 4, group A, member 2

decreases expression

Fluoxetine results in decreased expression of NR4A2 mRNA

NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877

G

nuclear receptor subfamily 4, group A, member 3

decreases expression

Fluoxetine results in decreased expression of NR4A3 mRNA

NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733

G

neurogranin

decreases expression

Fluoxetine results in decreased expression of NRGN mRNA

NCBI chr 8:37,255,462...37,263,659
Ensembl chr 8:37,256,930...37,257,516

G

neuritin 1

increases expression

Fluoxetine results in increased expression of NRN1 mRNA

NCBI chr17:28,129,969...28,138,898
Ensembl chr17:28,129,977...28,138,896

G

NAD(P) dependent steroid dehydrogenase-like

increases expression

Fluoxetine results in increased expression of NSDHL mRNA

NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142

G

neurotrophic receptor tyrosine kinase 2

increases expression
multiple interactions
increases phosphorylation

Fluoxetine results in increased expression of NTRK2 mRNA; Fluoxetine results in increased expression of NTRK2 mRNA alternative form
Fluoxetine inhibits the reaction [NTRK2 protein binds to AP2M1 protein]
Fluoxetine results in increased phosphorylation of NTRK2 protein
Fluoxetine inhibits the reaction [NTRK2 protein binds to AP2A2 protein]; Fluoxetine inhibits the reaction [NTRK2 protein binds to AP2B1 protein]; Fluoxetine inhibits the reaction [NTRK2 protein binds to AP2M1 protein]; Fluoxetine results in increased phosphorylation of and results in increased activity of NTRK2 protein

PMID:8601816 PMID:15456934 PMID:21666748 PMID:22396798 PMID:31631060

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

nucleobindin 1

affects expression

Fluoxetine affects the expression of NUCB1 mRNA

NCBI chr 1:95,968,325...95,999,183
Ensembl chr 1:95,968,326...96,003,220

G

nuclear protein 1, transcriptional regulator

increases expression

Fluoxetine results in increased expression of NUPR1 mRNA

PMID:15342952 PMID:17175557 PMID:17567588

NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281

G

oligodendrocyte transcription factor 2

increases expression

Fluoxetine results in increased expression of OLIG2 mRNA

NCBI chr11:30,475,510...30,478,886
Ensembl chr11:30,475,398...30,480,152

G

opioid receptor, mu 1

multiple interactions
increases expression

Fluoxetine inhibits the reaction [Methamphetamine results in decreased expression of OPRM1 mRNA]; Fluoxetine inhibits the reaction [Methamphetamine results in decreased expression of OPRM1 protein]
Fluoxetine results in increased expression of OPRM1 protein

PMID:16484055 PMID:21886566

NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409

G

osteoclastogenesis associated transmembrane protein 1

increases expression

Fluoxetine results in increased expression of OSTM1 mRNA

NCBI chr20:46,071,657...46,187,049
Ensembl chr20:46,153,075...46,187,023

G

orthodenticle homeobox 2

affects expression

Fluoxetine affects the expression of OTX2 mRNA

NCBI chr15:21,942,233...21,953,034
Ensembl chr15:21,943,191...21,953,416

G

oxytocin/neurophysin I prepropeptide

decreases expression

Fluoxetine results in decreased expression of OXT mRNA

NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490

G

oxytocin receptor

multiple interactions
increases expression

Fluoxetine affects the reaction [vasotocin, (beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-O-methyl-Tyr(2)-Thr(4)-Orn(8)-Tyr(9)-NH2 binds to OXTR protein]
Fluoxetine results in increased expression of OXTR protein

NCBI chr 4:145,598,549...145,614,674
Ensembl chr 4:145,599,561...145,614,674

G

prolyl 4-hydroxylase subunit beta

increases expression

Fluoxetine results in increased expression of P4HB mRNA

NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500

G

pantothenate kinase 3

increases expression

Fluoxetine results in increased expression of PANK3 mRNA

NCBI chr10:20,229,129...20,252,955
Ensembl chr10:20,229,129...20,252,955

G

progestin and adipoQ receptor family member 8

increases expression

Fluoxetine results in increased expression of PAQR8 mRNA

NCBI chr 9:23,312,521...23,362,175
Ensembl chr 9:23,312,585...23,362,340

G

paired box 3

affects expression

Fluoxetine affects the expression of PAX3 mRNA

NCBI chr 9:79,567,455...79,664,042
Ensembl chr 9:79,568,634...79,664,042

G

phosphate cytidylyltransferase 2, ethanolamine

increases expression

Fluoxetine results in increased expression of PCYT2 mRNA

NCBI chr10:105,888,769...105,896,182
Ensembl chr10:105,888,775...105,896,172

G

phosphodiesterase 4A

increases expression

Fluoxetine results in increased expression of PDE4A mRNA

NCBI chr 8:19,690,816...19,753,538
Ensembl chr 8:19,703,290...19,751,961

G

phosphodiesterase 4B

decreases expression
affects expression
increases expression

Fluoxetine results in decreased expression of PDE4B protein
Fluoxetine affects the expression of PDE4B mRNA
Fluoxetine results in increased expression of PDE4B mRNA

PMID:12504921 PMID:20222156 PMID:22291481

NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696

G

phosphodiesterase 4D

affects expression

Fluoxetine affects the expression of PDE4D mRNA alternative form

NCBI chr 2:40,014,933...41,529,190
Ensembl chr 2:40,019,933...41,525,884

G

phosphodiesterase 8B

increases expression

Fluoxetine results in increased expression of PDE8B mRNA

NCBI chr 2:26,275,117...26,479,725
Ensembl chr 2:26,276,635...26,509,209

G

prodynorphin

affects expression
decreases expression

Fluoxetine affects the expression of PDYN protein
Fluoxetine results in decreased expression of PDYN mRNA

PMID:14997015 PMID:15936043

NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334

G

proenkephalin

decreases expression

Fluoxetine results in decreased expression of PENK mRNA

PMID:9526047 PMID:15936043

NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129

G

period circadian regulator 1

decreases expression
decreases expression

Fluoxetine results in decreased expression of PER1 mRNA
fluoxetine decreases expression of Per1 mRNA in hippocampal formation and caudate-putamen

CTD
RGD

PMID:15994025 PMID:15994025

NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431

G

period circadian regulator 2

affects expression
decreases expression
increases expression

Fluoxetine affects the expression of PER2 mRNA
fluoxetine decreases expression of Per2 mRNA in caudate-putamen
fluoxetine increases expression of Per2 mRNA in hippocampal formation

CTD
RGD

PMID:15994025 PMID:15994025 PMID:15994025

RGD:405866348, RGD:405866348

NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459

G

phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1

increases expression

Fluoxetine results in increased expression of PIP4P1 mRNA

NCBI chr15:24,146,854...24,150,739
Ensembl chr15:24,146,856...24,150,702

G

phospholipase A2 group 4A

multiple interactions
increases expression

[[Fluoxetine binds to and results in increased activity of HTR2B protein] which results in increased activity of MAPK1 protein] which results in increased expression of PLA2G4A protein; [[Fluoxetine binds to and results in increased activity of HTR2B protein] which results in increased activity of MAPK3 protein] which results in increased expression of PLA2G4A protein; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A mRNA]; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A mRNA]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A protein]; RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A mRNA]; RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A protein]; U 0126 inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A mRNA]; U 0126 inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A protein]
Fluoxetine results in increased expression of PLA2G4A mRNA; Fluoxetine results in increased expression of PLA2G4A protein

NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266

G

phospholipase C beta 1

decreases expression

Fluoxetine results in decreased expression of PLCB1 mRNA; Fluoxetine results in decreased expression of PLCB1 protein

NCBI chr 3:122,059,988...122,772,896
Ensembl chr 3:122,060,031...122,772,869

G

phospholipase C-like 1

increases expression

Fluoxetine results in increased expression of PLCL1 mRNA

NCBI chr 9:56,901,573...57,238,782
Ensembl chr 9:56,901,534...57,238,782

G

plectin

decreases expression

Fluoxetine results in decreased expression of PLEC mRNA

NCBI chr 7:107,887,764...107,949,100
Ensembl chr 7:107,887,764...107,945,467

G

pro-melanin-concentrating hormone

decreases expression

Fluoxetine results in decreased expression of PMCH mRNA

NCBI chr 7:22,511,934...22,513,250
Ensembl chr 7:22,511,934...22,513,250

G

premelanosome protein

increases expression

Fluoxetine results in increased expression of PMEL mRNA

NCBI chr 7:1,138,202...1,148,735
Ensembl chr 7:1,138,586...1,148,746

G

patatin-like phospholipase domain containing 3

increases expression

Fluoxetine results in increased expression of PNPLA3 mRNA

NCBI chr 7:115,293,538...115,314,077
Ensembl chr 7:115,293,538...115,314,077

G

proopiomelanocortin

increases expression
decreases expression

Fluoxetine results in increased expression of POMC mRNA; Fluoxetine results in increased expression of POMC protein
Fluoxetine results in decreased expression of POMC mRNA

PMID:15936043 PMID:16042082 PMID:18359080

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

POU class 5 homeobox 1

affects expression

Fluoxetine affects the expression of POU5F1 mRNA

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

peroxisome proliferator activated receptor alpha

multiple interactions

[Fluoxetine affects the susceptibility to Ethanol] which affects the expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

multiple interactions
decreases expression
increases expression

Fluoxetine inhibits the reaction [Serotonin results in increased localization of PPARG protein]
vinpocetine inhibits the reaction [Fluoxetine results in decreased expression of PPARG mRNA]; vinpocetine inhibits the reaction [Fluoxetine results in decreased expression of PPARG protein]
Fluoxetine results in decreased expression of PPARG mRNA; Fluoxetine results in decreased expression of PPARG protein
Fluoxetine results in increased expression of PPARG mRNA

PMID:25766885 PMID:34669537 PMID:34897744

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase 1, regulatory (inhibitor) subunit 1B

affects phosphorylation
increases response to substance
multiple interactions
increases expression

Fluoxetine affects the phosphorylation of PPP1R1B protein
PPP1R1B protein results in increased susceptibility to Fluoxetine
PPP1R1B protein promotes the reaction [Fluoxetine affects the phosphorylation of GRIA1 protein]
Fluoxetine results in increased expression of PPP1R1B mRNA; Fluoxetine results in increased expression of PPP1R1B protein

NCBI chr10:83,347,731...83,356,775
Ensembl chr10:83,347,731...83,356,775

G

protein kinase C, gamma

decreases expression

Fluoxetine results in decreased expression of PRKCG mRNA

NCBI chr 1:65,832,851...65,860,676
Ensembl chr 1:65,832,855...65,859,384

G

protein kinase cGMP-dependent 1

multiple interactions

Fluoxetine inhibits the reaction [Monocrotaline results in decreased expression of PRKG1 protein]

NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080

G

prolactin

multiple interactions
increases expression

[olanzapine co-treated with Fluoxetine] results in increased expression of PRL protein
Fluoxetine results in increased expression of PRL protein

PMID:313977 PMID:9098464 PMID:16848655 PMID:19896213

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

serine protease 23

decreases expression

Fluoxetine results in decreased expression of PRSS23 mRNA

NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091

G

proteasome 20S subunit alpha 3

affects expression

Fluoxetine affects the expression of PSMA3 mRNA

NCBI chr 6:89,483,741...89,503,775
Ensembl chr 6:89,483,727...89,504,965

G

proteasome 20S subunit beta 4

decreases expression

Fluoxetine results in decreased expression of PSMB4 mRNA

NCBI chr 2:182,442,757...182,445,532
Ensembl chr 2:182,442,756...182,445,746

G

phosphotriesterase related

decreases expression

Fluoxetine results in decreased expression of PTER mRNA

NCBI chr17:76,058,388...76,119,633
Ensembl chr17:76,058,503...76,119,627

G

prostaglandin D2 synthase

decreases expression
increases expression

Fluoxetine results in decreased expression of PTGDS mRNA
Fluoxetine results in increased expression of PTGDS mRNA

PMID:17105902 PMID:34897744

NCBI chr 3:8,281,899...8,284,833
Ensembl chr 3:8,281,899...8,284,833

G

prostaglandin-endoperoxide synthase 1

increases expression

Fluoxetine results in increased expression of PTGS1 mRNA

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

prostaglandin-endoperoxide synthase 2

decreases expression
increases expression

Fluoxetine results in decreased expression of PTGS2 mRNA; Fluoxetine results in decreased expression of PTGS2 protein
Fluoxetine results in increased expression of PTGS2 mRNA

PMID:17033635 PMID:21554931 PMID:21966942 PMID:34897744

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine kinase 2 beta

decreases expression

Fluoxetine results in decreased expression of PTK2B mRNA

NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282

G

pyroglutamylated RFamide peptide receptor

decreases expression

Fluoxetine results in decreased expression of QRFPR mRNA

NCBI chr 2:119,053,083...119,096,864
Ensembl chr 2:119,053,511...119,096,792

G

RAB29, member RAS oncogene family

increases expression

Fluoxetine results in increased expression of RAB29 mRNA

NCBI chr13:43,307,757...43,313,420
Ensembl chr13:43,307,775...43,313,417

G

RCC1 and BTB domain containing protein 1

increases expression

Fluoxetine results in increased expression of RCBTB1 mRNA

NCBI chr15:33,319,586...33,362,421
Ensembl chr15:33,319,586...33,365,302

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases activity

Fluoxetine inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Fluoxetine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]
Fluoxetine results in increased activity of RELA protein

PMID:16413968 PMID:21575647

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

reelin

increases expression

Fluoxetine results in increased expression of RELN mRNA

NCBI chr 4:12,736,177...13,162,956
Ensembl chr 4:12,736,130...13,162,211

G

regulator of G-protein signaling 3

increases expression

Fluoxetine results in increased expression of RGS3 mRNA

NCBI chr 5:76,022,038...76,161,895
Ensembl chr 5:76,022,001...76,161,894

G

reprimo-like

decreases expression

Fluoxetine results in decreased expression of RPRML mRNA

NCBI chr10:88,560,248...88,561,252
Ensembl chr10:88,560,248...88,561,252

G

RT1 class II, locus Ha

affects expression

Fluoxetine affects the expression of HLA-DPA1 mRNA

NCBI chr20:4,760,631...4,770,662
Ensembl chr20:4,760,118...4,770,244

G

S100 calcium binding protein B

increases response to substance
increases expression

S100B protein results in increased susceptibility to Fluoxetine
Fluoxetine results in increased expression of S100B protein
Fluoxetine results in increased expression of S100B mRNA; Fluoxetine results in increased expression of S100B protein

PMID:12960766 PMID:20857517 PMID:22113448

NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743

G

sterile alpha motif domain containing 4A

decreases expression

Fluoxetine results in decreased expression of SAMD4A mRNA

NCBI chr15:20,135,994...20,352,131
Ensembl chr15:20,134,377...20,348,380

G

sterol-C5-desaturase

increases expression

Fluoxetine results in increased expression of SC5D mRNA

NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273

G

stearoyl-CoA desaturase

increases expression

Fluoxetine results in increased expression of SCD mRNA

PMID:16324787 PMID:37386098

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

selenoprotein I

increases expression

Fluoxetine results in increased expression of SELENOI mRNA

NCBI chr 6:26,073,127...26,111,326
Ensembl chr 6:26,072,648...26,111,314

G

serpin family A member 3N

increases expression

Fluoxetine results in increased expression of SERPINA3 mRNA

PMID:15342952 PMID:17175557 PMID:17567588

NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433

G

serpin family I member 1

increases expression

Fluoxetine results in increased expression of SERPINI1 mRNA

NCBI chr 2:160,346,403...160,433,135
Ensembl chr 2:160,346,758...160,433,135

G

serum/glucocorticoid regulated kinase 1

increases expression

Fluoxetine results in increased expression of SGK1 mRNA

NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283

G

solute carrier family 13 member 4

decreases expression

Fluoxetine results in decreased expression of SLC13A4 mRNA

NCBI chr 4:63,943,369...63,988,852
Ensembl chr 4:63,943,395...63,988,857

G

solute carrier family 17 member 7

increases expression
decreases expression

Fluoxetine results in increased expression of SLC17A7 mRNA; Fluoxetine results in increased expression of SLC17A7 protein
Fluoxetine results in decreased expression of SLC17A7 mRNA

PMID:16111724 PMID:17033635

NCBI chr 1:95,649,709...95,661,591
Ensembl chr 1:95,649,745...95,661,588

G

solute carrier family 22 member 2

multiple interactions

Fluoxetine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

solute carrier family 27 member 5

increases expression
multiple interactions

Fluoxetine results in increased expression of SLC27A5 mRNA
SC 560 inhibits the reaction [Fluoxetine results in increased expression of SLC27A5 mRNA]

NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172

G

solute carrier family 2 member 3

decreases expression

Fluoxetine results in decreased expression of SLC2A3 mRNA

PMID:15342952 PMID:17567588

NCBI chr 4:155,960,944...156,026,000
Ensembl chr 4:155,960,946...156,025,472

G

solute carrier family 30 member 3

decreases expression

Fluoxetine results in decreased expression of SLC30A3 mRNA

NCBI chr 6:25,264,310...25,284,720
Ensembl chr 6:25,275,528...25,284,720

G

solute carrier family 32 member 1

decreases expression

Fluoxetine results in decreased expression of SLC32A1 protein

NCBI chr 3:147,267,373...147,271,842
Ensembl chr 3:147,267,373...147,271,844

G

solute carrier family 38, member 2

increases expression

Fluoxetine results in increased expression of SLC38A2 mRNA

NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436

G

solute carrier family 6 member 15

multiple interactions

[Fluoxetine co-treated with Caffeine] results in decreased expression of SLC6A15 mRNA

NCBI chr 7:38,553,055...38,607,239
Ensembl chr 7:38,553,196...38,607,239

G

solute carrier family 6 member 2

multiple interactions

Fluoxetine inhibits the reaction [SLC6A2 protein results in increased import of Biogenic Monoamines analog]; Fluoxetine inhibits the reaction [SLC6A2 protein results in increased import of Fluorescent Dyes]

NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357

G

solute carrier family 6 member 3

multiple interactions
affects expression
affects response to substance

SLC6A3 mutant form affects the reaction [Fluoxetine affects the abundance of Dopamine]
Fluoxetine inhibits the reaction [SLC6A3 protein results in increased import of Biogenic Monoamines analog]; Fluoxetine inhibits the reaction [SLC6A3 protein results in increased import of Fluorescent Dyes]; Fluoxetine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]
Fluoxetine affects the expression of SLC6A3
SLC6A3 protein affects the susceptibility to Fluoxetine

PMID:11797063 PMID:14691264 PMID:26475043 PMID:28506818 PMID:31009648

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

solute carrier family 6 member 4

affects response to substance
decreases activity
decreases response to substance
affects expression
multiple interactions
decreases expression
increases response to substance
decreases localization
increases expression

SLC6A4 affects the susceptibility to Fluoxetine; SLC6A4 protein affects the susceptibility to Fluoxetine
Fluoxetine results in decreased activity of SLC6A4 protein
SLC6A4 gene polymorphism results in decreased susceptibility to Fluoxetine
Fluoxetine affects the expression of SLC6A4 protein
Fluoxetine binds to and results in decreased activity of SLC6A4 protein; Fluoxetine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]; Fluoxetine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]
Fluoxetine results in decreased expression of SLC6A4 mRNA; Fluoxetine results in decreased expression of SLC6A4 protein
SLC6A4 gene polymorphism results in increased susceptibility to Fluoxetine; SLC6A4 protein results in increased susceptibility to Fluoxetine
Fluoxetine results in decreased localization of SLC6A4 protein
[Estradiol co-treated with Fluoxetine] results in increased expression of SLC6A4 mRNA; [Fluoxetine results in decreased expression of SLC6A4 mRNA] which results in decreased abundance of Serotonin; Org 34850 promotes the reaction [Fluoxetine results in decreased expression of SLC6A4 protein]
Fluoxetine results in increased expression of SLC6A4 mRNA

PMID:8914125 PMID:14573314 PMID:14604448 PMID:15936043 PMID:16272152 More...

NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384

G

solute carrier family 7 member 11

increases expression

Fluoxetine results in increased expression of SLC7A11 mRNA

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

SMAD family member 1

multiple interactions

Fluoxetine inhibits the reaction [Monocrotaline results in decreased expression of SMAD1 mRNA]; Fluoxetine inhibits the reaction [Monocrotaline results in decreased phosphorylation of SMAD1 protein]

NCBI chr19:28,513,130...28,573,665
Ensembl chr19:28,513,131...28,573,651

G

sphingomyelin phosphodiesterase 1

multiple interactions
decreases activity
increases response to substance

[Fluoxetine results in decreased expression of and results in decreased activity of SMPD1 protein] which results in decreased abundance of Ceramides; Fluoxetine results in decreased expression of and results in decreased activity of SMPD1 protein
Fluoxetine results in decreased activity of SMPD1 protein
SMPD1 protein results in increased susceptibility to Fluoxetine

NCBI chr 1:159,892,946...159,896,789
Ensembl chr 1:159,892,859...159,896,794

G

staphylococcal nuclease and tudor domain containing 1

increases expression

Fluoxetine results in increased expression of SND1 mRNA

NCBI chr 4:57,095,205...57,494,501
Ensembl chr 4:57,095,208...57,530,843

G

SRY-box transcription factor 2

affects expression

Fluoxetine affects the expression of SOX2 mRNA

NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338

G

Sp5 transcription factor

affects expression

Fluoxetine affects the expression of SP5 mRNA

NCBI chr 3:55,274,931...55,277,733
Ensembl chr 3:55,274,931...55,277,733

G

SPG21 abhydrolase domain containing, maspardin

increases expression

Fluoxetine results in increased expression of SPG21 mRNA

NCBI chr 8:65,980,992...66,008,537
Ensembl chr 8:65,980,962...66,008,536

G

sprouty RTK signaling antagonist 2

affects expression

Fluoxetine affects the expression of SPRY2 mRNA

NCBI chr15:82,692,291...82,697,408
Ensembl chr15:82,692,143...82,698,009

G

squalene epoxidase

decreases expression
increases expression

Fluoxetine results in decreased expression of SQLE mRNA
Fluoxetine results in increased expression of SQLE mRNA

PMID:21852994 PMID:37386098

NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618

G

sequestosome 1

decreases expression

Fluoxetine results in decreased expression of SQSTM1 mRNA

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

serine and arginine rich splicing factor 5

affects expression

Fluoxetine affects the expression of SRSF5 mRNA

NCBI chr 6:100,605,165...100,610,192
Ensembl chr 6:100,605,456...100,610,177

G

steroidogenic acute regulatory protein

multiple interactions
decreases expression

resveratrol inhibits the reaction [Fluoxetine results in decreased expression of STAR mRNA]

NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672

G

StAR-related lipid transfer domain containing 4

increases expression

Fluoxetine results in increased expression of STARD4 mRNA

NCBI chr18:24,814,683...24,830,024
Ensembl chr18:24,817,107...24,830,024

G

stanniocalcin 1

increases expression

Fluoxetine results in increased expression of STC1 mRNA

NCBI chr15:44,299,591...44,311,695
Ensembl chr15:44,299,621...44,310,264

G

syntaxin binding protein 1

increases expression

Fluoxetine results in increased expression of STXBP1 mRNA

NCBI chr 3:16,076,725...16,138,431
Ensembl chr 3:16,076,391...16,138,369

G

synapsin I

increases expression

Fluoxetine results in increased expression of SYN1 mRNA

NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396

G

synaptophysin

increases expression
decreases expression

Fluoxetine results in increased expression of SYP mRNA
Fluoxetine results in decreased expression of SYP mRNA

PMID:17950272 PMID:20857517

NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745

G

transgelin

decreases expression

Fluoxetine results in decreased expression of TAGLN mRNA

PMID:15342952 PMID:17175557 PMID:17567588

NCBI chr 8:46,224,939...46,230,413
Ensembl chr 8:46,222,472...46,230,668

G

T-box transcription factor 6

affects expression

Fluoxetine affects the expression of TBX6 mRNA

NCBI chr 1:181,387,851...181,392,762
Ensembl chr 1:181,388,684...181,392,593

G

T-box transcription factor T

affects expression

Fluoxetine affects the expression of T mRNA

NCBI chr 1:52,298,104...52,309,813
Ensembl chr 1:52,298,099...52,305,864

G

transcobalamin 2

increases expression

Fluoxetine results in increased expression of TCN2 mRNA

NCBI chr14:78,813,343...78,828,549
Ensembl chr14:78,813,343...78,828,489

G

tyrosine hydroxylase

decreases expression
affects expression
increases expression

Fluoxetine results in decreased expression of TH mRNA
Fluoxetine affects the expression of TH
Fluoxetine results in increased expression of TH mRNA

PMID:1351783 PMID:15936043 PMID:20374287 PMID:20626387 PMID:20857517 More...

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

TIMP metallopeptidase inhibitor 1

multiple interactions

[9,10-Dimethyl-1,2-benzanthracene co-treated with Raloxifene Hydrochloride co-treated with Fluoxetine] affects the expression of TIMP1 protein

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

transmembrane channel-like 4

decreases expression

Fluoxetine results in decreased expression of TMC4 mRNA

NCBI chr 1:65,539,777...65,551,683
Ensembl chr 1:65,539,721...65,551,677

G

tumor necrosis factor

multiple interactions
increases expression
decreases activity

Fluoxetine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Fluoxetine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Fluoxetine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
Fluoxetine results in increased expression of TNF protein
Fluoxetine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; Fluoxetine inhibits the reaction [Reserpine results in increased expression of TNF protein]; Fluoxetine promotes the reaction [caryophyllene inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; vinpocetine inhibits the reaction [Fluoxetine results in increased expression of TNF protein]
Fluoxetine results in increased expression of TNF mRNA
Fluoxetine results in decreased activity of TNF protein
Fluoxetine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]; Fluoxetine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]

PMID:16413968 PMID:17477857 PMID:21497159 PMID:21575647 PMID:30529211 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF superfamily member 11

multiple interactions

Fluoxetine inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Fluoxetine inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Fluoxetine inhibits the reaction [TNFSF11 protein results in increased expression of MMP9 mRNA]

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

G

tumor protein p53

increases expression

Fluoxetine results in increased expression of TRP53 mRNA
Fluoxetine results in increased expression of TP53 mRNA

PMID:18836303 PMID:21497159

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

tryptophan hydroxylase 1

increases expression

Fluoxetine results in increased expression of TPH1 mRNA

PMID:15631896 PMID:21083617

NCBI chr 1:97,157,375...97,178,415
Ensembl chr 1:97,157,409...97,178,344

G

tryptophan hydroxylase 2

increases expression
decreases expression
increases response to substance
affects expression
affects response to substance
multiple interactions

Fluoxetine results in increased expression of TPH2 mRNA
Fluoxetine results in decreased expression of TPH2 mRNA
TPH2 results in increased susceptibility to Fluoxetine
Fluoxetine affects the expression of TPH2 mRNA
TPH2 protein affects the susceptibility to Fluoxetine
[Estradiol co-treated with Fluoxetine] results in increased expression of TPH2 mRNA

PMID:11901216 PMID:16982082 PMID:17321503 PMID:17950541 PMID:20374287 More...

NCBI chr 7:50,685,694...50,789,424
Ensembl chr 7:50,685,694...50,789,424

G

tropomyosin 1

decreases expression

Fluoxetine results in decreased expression of TPM1 mRNA

NCBI chr 8:67,635,479...67,662,330
Ensembl chr 8:67,635,479...67,662,802

G

thyroid stimulating hormone subunit beta

increases expression

Fluoxetine results in increased expression of TSHB mRNA

NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559

G

testis-specific serine kinase 2

decreases expression

Fluoxetine results in decreased expression of TSSK2 mRNA

NCBI chr11:83,086,578...83,087,933

G

transthyretin

increases expression

Fluoxetine results in increased expression of TTR mRNA

NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008

G

tubulin, beta 3 class III

decreases expression

Fluoxetine results in decreased expression of TUBB3 mRNA

NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243

G

UDP-N-acetylglucosamine pyrophosphorylase 1 like 1

increases expression

Fluoxetine results in increased expression of UAP1L1 mRNA

NCBI chr 3:8,172,335...8,180,505
Ensembl chr 3:8,173,216...8,180,443

G

vascular endothelial growth factor A

increases expression
multiple interactions

Fluoxetine results in increased expression of VEGFA mRNA
[9,10-Dimethyl-1,2-benzanthracene co-treated with Raloxifene Hydrochloride co-treated with Fluoxetine] affects the expression of VEGFA protein

PMID:21301813 PMID:31332895

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

VGF nerve growth factor inducible

increases expression

Fluoxetine results in increased expression of VGF mRNA

NCBI chr12:19,637,313...19,645,123
Ensembl chr12:19,637,320...19,640,341

G

very low density lipoprotein receptor

increases expression

Fluoxetine results in increased expression of VLDLR protein
Fluoxetine results in increased expression of VLDLR mRNA

PMID:19359144 PMID:24356939

NCBI chr 1:224,813,539...224,850,400
Ensembl chr 1:224,814,377...224,845,920

G

VPS26 endosomal protein sorting factor C

increases expression

Fluoxetine results in increased expression of VPS26C mRNA

NCBI chr11:33,813,467...33,841,883
Ensembl chr11:33,792,389...33,841,447

G

wolframin ER transmembrane glycoprotein

decreases expression

Fluoxetine results in decreased expression of WFS1 mRNA

NCBI chr14:73,810,478...73,834,993
Ensembl chr14:73,810,404...73,835,602

G

WD repeat domain, phosphoinositide interacting 1

increases expression

Fluoxetine results in increased expression of WIPI1 mRNA

PMID:15342952 PMID:17175557 PMID:17567588

NCBI chr10:94,542,946...94,580,174
Ensembl chr10:94,542,946...94,579,846

G

Wnt family member 3A

increases phosphorylation
affects expression

Fluoxetine results in increased phosphorylation of WNT3A protein
Fluoxetine affects the expression of WNT3A mRNA

PMID:21048974 PMID:29893963

NCBI chr10:44,034,174...44,078,366
Ensembl chr10:44,034,194...44,078,324

G

X-linked inhibitor of apoptosis

increases expression

Fluoxetine results in increased expression of XIAP mRNA

NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700

G

exportin 1

decreases expression
increases expression

Fluoxetine results in decreased expression of XPO1 mRNA
Fluoxetine results in increased expression of XPO1 mRNA

NCBI chr14:97,233,282...97,275,536
Ensembl chr14:97,233,270...97,275,498

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon

affects expression

Fluoxetine affects the expression of YWHAE mRNA

NCBI chr10:60,584,665...60,622,352
Ensembl chr10:60,584,652...60,671,589

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta

affects expression

Fluoxetine affects the expression of YWHAH mRNA

NCBI chr14:77,696,332...77,705,715
Ensembl chr14:77,696,333...77,705,741

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta

increases expression

Fluoxetine results in increased expression of YWHAZ mRNA; Fluoxetine results in increased expression of YWHAZ protein

NCBI chr 7:67,941,353...67,963,651
Ensembl chr 7:67,940,017...67,963,668

fluvoxamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases activity

Fluvoxamine inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Fluvoxamine results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

affects response to substance

ABCB1A protein affects the susceptibility to Fluvoxamine

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

affects response to substance

ABCB1B protein affects the susceptibility to Fluvoxamine

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily B member 4

decreases activity

Fluvoxamine results in decreased activity of ABCB4 protein

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

arginine vasopressin

increases expression

Fluvoxamine results in increased expression of AVP protein

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

caspase 3

increases activity
multiple interactions

Fluvoxamine results in increased activity of CASP3 protein
Palmitic Acid promotes the reaction [Fluvoxamine results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

increases activity
multiple interactions

Fluvoxamine results in increased activity of CASP7 protein
Palmitic Acid promotes the reaction [Fluvoxamine results in increased activity of CASP7 protein]

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity

Fluvoxamine results in decreased activity of CYP19A1 protein

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
decreases activity
increases response to substance
increases expression

[Fluvoxamine results in decreased activity of CYP1A2 protein] which results in decreased chemical synthesis of 16-O-demethylaconitine metabolite; [Fluvoxamine results in decreased activity of CYP1A2 protein] which results in decreased metabolism of Phenacetin; [Fluvoxamine results in decreased activity of CYP1A2 protein] which results in increased chemical synthesis of Aconitine metabolite; CYP1A2 protein binds to and affects the metabolism of Fluvoxamine; Enoxacin inhibits the reaction [CYP1A2 protein affects the metabolism of Fluvoxamine]; Fluvoxamine inhibits the reaction [CYP1A2 protein affects the metabolism of olanzapine]; Fluvoxamine inhibits the reaction [CYP1A2 protein affects the metabolism of Theophylline]; Fluvoxamine inhibits the reaction [CYP1A2 protein results in increased chemical synthesis of Acetaminophen]; Fluvoxamine inhibits the reaction [CYP1A2 protein results in increased chemical synthesis of clozapine N-oxide]; Fluvoxamine inhibits the reaction [CYP1A2 protein results in increased chemical synthesis of norclozapine]; Fluvoxamine inhibits the reaction [CYP1A2 protein results in increased metabolism of Phenacetin]
CYP1A2 protein results in increased susceptibility to Fluvoxamine
[Fluvoxamine results in decreased activity of CYP1A2 protein] which results in decreased metabolism of Caffeine
fluvoxamine increases expression of CYP1A2 mRNA and protein in cervical cancer cells

CTD
RGD

PMID:9029748 PMID:11763009 PMID:15545309 PMID:15845683 PMID:15905806 More...

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

Fluvoxamine inhibits the reaction [CYP3A4 protein results in increased oxidation of and results in increased activity of Haloperidol]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions

Fluvoxamine inhibits the reaction [CYP3A5 protein results in increased oxidation of and results in increased activity of Haloperidol]

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

glutamate decarboxylase 1

multiple interactions

[Haloperidol co-treated with Fluvoxamine] affects the expression of GAD1 protein

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

5-hydroxytryptamine receptor 2A

affects response to substance

HTR2A gene SNP affects the susceptibility to Fluvoxamine

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

G

intercellular adhesion molecule 1

multiple interactions

Fluvoxamine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of ICAM1 mRNA]
Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of ICAM1 mRNA]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

potassium voltage-gated channel subfamily H member 2

multiple interactions
decreases activity

[Terfenadine co-treated with Fluvoxamine] binds to and results in decreased activity of KCNH2 protein; Fluvoxamine binds to and results in decreased activity of KCNH2 protein; Fluvoxamine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]
Fluvoxamine results in decreased activity of KCNH2 protein

PMID:20071423 PMID:21158687 PMID:24052561

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

nitric oxide synthase 2

increases expression
multiple interactions

Fluvoxamine results in increased expression of NOS2 mRNA
Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]
Fluvoxamine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]

PMID:12429386 PMID:27803785

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

protein kinase C, beta

multiple interactions

[Haloperidol co-treated with Fluvoxamine] affects the expression of PRKCB protein

NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536

G

prostaglandin-endoperoxide synthase 2

multiple interactions

Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]
Fluvoxamine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 mRNA]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

sodium voltage-gated channel alpha subunit 5

decreases activity
affects response to substance

Fluvoxamine results in decreased activity of SCN5A protein
SCN5A protein affects the susceptibility to Fluvoxamine

NCBI chr 8:119,220,905...119,318,816
Ensembl chr 8:119,220,905...119,318,769

G

vascular cell adhesion molecule 1

multiple interactions

Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of VCAM1 mRNA]
Fluvoxamine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of VCAM1 mRNA]

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19890
role	19839
application	19703
solvent	17229
(trifluoromethyl)benzene	440
4-(trifluoromethyl)phenol	0
flufenamate	0
flufenamic acid	42
fluoxetine	402
fluvoxamine	20
Path 2
Term	Annotations
CHEBI ontology	19890
subatomic particle	19867
composite particle	19888
hadron	19888
baryon	19888
nucleon	19867
atomic nucleus	19888
atom	19888
main group element atom	19806
main group molecular entity	19806
s-block molecular entity	19641
hydrogen molecular entity	19622
hydrides	19150
organic hydride	18682
organic fundamental parent	18682
hydrocarbon	18432
halohydrocarbon	15848
haloalkane	12910
fluoroalkane	9227
fluoromethanes	6776
tetrafluoromethane	6771
trifluoromethyl group	6776
(trifluoromethyl)benzenes	6771
(trifluoromethyl)benzene	440
4-(trifluoromethyl)phenol	0
flufenamate	0
flufenamic acid	42
fluoxetine	402
fluvoxamine	20

paths to the root